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Abstract 
Risk factors influencing long-term survival and nursing home placement in stroke 
survivors and patients with carotid stenosis 
Stroke is one of the leading causes of mortality and morbidity worldwide and one of 
the most devastating of all neurological conditions. Due to the many advances that 
have been made in terms of prevention and mortality in cardiovascular diseases, the 
mortality from stroke has declined steadily and more patients survive their strokes. 
Short-term mortality is intensely studied. Knowledge of long-term mortality and its 
clinical predictors offers the opportunity to better control the risk factors in the 
follow-up after a stroke.  
We have investigated long-term survival for up to 12.8 years and causes of death in 
230 patients with ≥40 % ICA-stenosis that is a known risk factor for stroke regarding 
statin treatment.  The results indicate that use of statins seems to increase long-term 
survival in patients with established carotid artery stenosis significantly compared to 
patients not using statins. 
We also examined the long-term mortality for up to 16.4 years in 1137 patients with 
acute stroke and compared it to a matched, stroke-free control group. We identified 
risk factors present at index stroke that might predict long-term mortality. The results 
indicate that stroke patients surviving the first year after stroke have a markedly 
increased but stable mortality rate during long-term follow-up compared to stroke 
free controls. Changes in creatinine, homocysteine and glucose could be addressed 
more aggressively as a standard routine after acute stroke. 
The 452 patients belonging to the municipality of Stavanger were followed for up to 
15.4 years regarding nursing home placement (NHP). Almost 90% of the stroke 
patients could initially be discharged to their homes but they needed earlier and more 
often NHP in the long run than the stroke-free controls, but they did not stay longer. 
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1.1 Brief history and definition of acute cerebral stroke 
The word “stroke” was first introduced into medicine in 1689 by William Cole in “A 
Physico-Medical Essay Concerning the late frequencies of Apoplexies” (1). Before 
this, very acute non traumatic brain injury was described as “apoplexy” – a concept 
established by Hippocrates circa 400 BC (2). 
The World Health Organization (WHO) defines stroke as: “rapidly developing 
clinical signs of focal (or global) disturbance of cerebral function, with symptoms 
lasting 24h or longer or leading to death, with no apparent cause other than of 
vascular origin” (3, 4). The pathological background is either ischemic or 
hemorrhagic disturbance of the cerebral blood circulation.  
 
1.2 Stroke subtypes 
1.2.1 Ischemic stroke (infarction) 
An expert consensus group convened by American Heart Association/American 
Stroke Association (AHA) modified the definition of an ischemic stroke in 2013 to 
“An episode of neurological dysfunction caused by focal cerebral, spinal or retinal 
infarction” (5). 
Cerebral infarction results from the obstruction of cerebral and/or cervical arteries 
with hypoperfusion and ischemia in the territory of the occluded artery. The 
obstruction can be due to thrombosis of a pre-existent stenosis or due to embolism 
from a more distal artery wall lesion. Arteriosclerotic stenosis, dissection and 
vasculitis cause changes in artery walls that can contribute to the occlusion. An 
embolism is a blockage-causing piece of material that is delivered by the bloodstream 
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and blocks an intracerebral artery. The most common origin is in the heart, the aorta 
or the carotid or vertebral arteries. About 85% of all strokes are ischemic. 
 
1.2.2 Hemorrhagic stroke 
The definition of a hemorrhagic stroke (ICH) was redefined by the AHA in 2013: 
“Rapidly developing clinical signs of neurological dysfunction attributable to a focal 
collection of blood within the brain parenchyma or ventricular system that is not 
caused by trauma” (5). Spontaneous intracerebral hemorrhages are mainly due to 
arteriolar hypertensive disease. Coagulation disorders, vascular malformations within 
the brain and diet (such as high alcohol consumption, drug abuse and low cholesterol 
concentration) are more rare causes. Cortical amyloid angiopathy, the deposition of 
β-amyloid in the media and adventitia of small and mid-sized arteries, is a cause of 
cortical hemorrhages especially occurring in elderly patients leading to multiple 
spontaneous smaller bleedings. These can be “silent” without a history of acute 
neurological dysfunction attributable to the lesion. Hemorrhagic strokes are less 
common than ischemic stroke but they are associated with higher mortality and 
morbidity than ischemic strokes (6). About 15% of all strokes are hemorrhagic. 
 
1.2.3 Subarachnoidal bleeding  
This subgroup of hemorrhagic stroke (up to 7%) (7) is mainly due to spontaneous 
rupture of aneurysms at the bifurcations of large arteries at the inferior surface of the 
brain. A stroke caused by subarachnoidal hemorrhage (SAH) is defined as “rapidly 
developing signs of neurological dysfunction and/or headache because of bleeding 
into the subarachnoid space (the space between the arachnoid membrane and the pia 
mater of the brain or spinal cord), which is not caused by trauma” (5). Often, they do 
not cause direct injury to the brain and are excluded from stroke-studies, but beside 
acute and intense headache the symptoms may be in accordance with the stroke 
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definitions. The mortality is high (45%) (8) and the survivors of a subarachnoidal 
bleeding often have a high rate of disability (9, 10).  
 
1.2.4 Transient ischemic attack (TIA) 
The Stroke Council of the American Heart Association (AHA) defined in 2009 a TIA 
as “a transient episode of neurological dysfunction caused by focal brain, spinal cord, 
or retinal ischemia without acute infarction” (11). A TIA is a temporary blockage of 
blood flow to the brain and associated with increased likelihood of a coming stroke: 
Thus, a TIA is often labeled as a “warning stroke” and offers an opportunity to 
initiate prophylactic treatment (12, 13). Former definitions were time based and 
presumed that the neurological symptoms dissolved within 24 hours. However, 
advances in radiology as high-resolution CT and especially diffusion-weighted MRI 
have shown that many short-lasting ischemic episodes are associated with infarction, 
making the time-limits inconsistent and outdated. Approximately 15% of all strokes 
are preceded by a TIA (14, 15), and the risk of a stroke following a TIA is up to 17% 
after three months (16). 
 
1.3 Epidemiology 
Stroke researchers in Norway calculated in 2007 that there would be approximately 
11.000 first-ever strokes and 3500 recurrent ones per year for the next years 
according to incidence numbers (17) and population statistics (18). According to the 
national Stroke Register, 8538 strokes were reported in 2015 but the data here only 
cover 84% of the strokes registered in the national Norwegian patient register (19). 
But, as in the rest of the world the incidence is expected to increase with up to 50% 
until 2030 due to the ageing population (20, 21). The burden of stroke due to illness, 
early death and disability is set to double worldwide within the next 15 years (22). In 
Norway the median age at stroke is 75 years (mean age 77.5 years for women and 
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71.9 years for men) (19), in the UK, the mean age at first stroke for men is 74 years 
and for women 80 years (23).  
The lifetime risk for suffering a stroke remains relatively constant until age 75, 
approximating 1 in 5 for women and 1 in 6 for men (24). In 2010, there were almost 
17 million first-time strokes worldwide (22). The age-standardized prevalence rate of 
stroke in developed countries for people aged ≥ 65 years ranges from 46 to 72 per 
1000 population (7). In the younger age groups up to 75 years, more stroke patients 
are male (25) but in total more females suffer a stroke and accordingly their lifetime 
risk and direct mortality is higher (26). Overall stroke prevalence in the United States 
is 2,7% (27). 
When considered separately from other cardiovascular diseases (CVDs), stroke is 
number two among causes of death, behind diseases of the heart but in front of 
chronic lower respiratory and chronic obstructive disease, cancer, and unintentional 
injuries/accidents in the world (28). In the low-income countries, it is number three 
after lower respiratory diseases and diarrheal diseases (28). In the USA stroke has 
fallen to fourth most common cause of death, overtaken by lower respiratory diseases 
(29). Stroke deaths accounted for 11.8% of total deaths worldwide in 2013 (30). From 
1970 to 2008 there has been a 42% decrease in stroke incidence in high-income 
countries and more than a 100% increase in low to middle income countries, where 
the majority of global stroke burden now resides (31, 32).  
The decline in stroke rates in the developed countries occurred over a period of 
significant increase in the use of medications that attenuate stroke risk: Statin use 
increased from 4% in 1992 to 41% in 2008 and antihypertensive drug use increased 
from 53% to 74% in the same time (33, 34). Cost-effective medications such as 
aspirin, statins, and blood pressure lowering agents still remain unaffordable in large 
parts of the world.  
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1.4 Etiology and pathophysiology of acute cerebral stroke 
The etiology of a stroke is brain tissue hypoperfusion caused by either ischemia or 
hemorrhage, and proportions range from 67% to 81% for ischemic stroke, 7% to 20% 
for primary intracerebral hemorrhage and 1% to 7% for subarachnoid hemorrhage 
while 2% to 15% remain undetermined (31). Other causes for cerebral hypoperfusion 
are sinus thrombosis (impaired cerebral venous drainage), vascular malformations, 
vasculitis, hematologic disorders and systemic hypoperfusion (septic shock, cardiac 
arrest i.a.).  
Stroke is a very heterogenous and multifactorial disease. In addition to other, 
conventional risk factors genetic factors may contribute to a significant proportion of 
stroke. The genetics can be polygenic, monogenic or multifactorial (35, 36) but 
single-gene mutations count for approximately only 1% of ischemic strokes. 
However, there are certain known gene mutations leading to increased risk for 
strokes. Examples are mutations in the NOTCH3-receptor leading to CADASIL and 
mutations in α-galactosidase A leading to Fabry disease (35).     
During local or systemic hypoperfusion insufficiency of blood supply leads to 
shortage of oxygen and glucose to the brain tissue. This leads to ischemic, necrotic 
cell death and is characterized by swelling (oncosis) of the mitochondrions, 
cytoplasma and nucleus and cytoplasm vacuolization (37). Apoptotic death will also 
occur, induced by several different stimuli as nitric oxide production, free radical 
formation and increased intracellular calcium which all prevail during ischemia (38). 
Specific brain regions and distinct neuronal populations appear to be more commonly 
affected due to higher metabolic rates or location in vascular border zones which 
make them more vulnerable (39). The hippocampus, the cerebellum, the basal ganglia 
and the watershed area belong to these regions.  
 
 20 
1.5 Clinical manifestations 
A stroke manifests with sudden loss of function corresponding to the location of the 
underlying vascular disturbance. Most often acute motor and sensory deficits like 
paresis and numbness can be seen. Language disturbances as aphasia or dysarthria are 
also common and a stroke might present with sudden vertigo, headache, balance 
problems, visual field affections or a combination of the aforementioned symptoms. 
 
1.6 Clinical examination  
When a patient arrives at the hospital with an acute stroke, a clinical examination is 
performed to validate the neurologic deficits and to confirm the clinical stroke 
diagnosis. Radiologic neuroimaging is done primarily to exclude contraindications to 
acute thrombolytic treatment (see 1.7.1 Radiologic neuroimaging). The clinical 
examination is standardized and systematic, including systematic assessment tools 
that provide a quantitative measure of stroke-related neurologic deficit. Today, the 
National Institutes of Health Stroke Scale (NIHSS) is most commonly used. The 
Scandinavian Stroke Scale (SSS) is an alternative assessment tool that was used 
frequently some years ago. It was the standard tool used at the Stavanger University 
Hospital (SUS) before 2009. 
 
1.6.1 SSS 
The Scandinavian Stroke Study Group performed in 1985 a multicenter study in 
Scandinavia to evaluate the effect of early hemodilution treatment in ischemic stroke 
patients. They did not find an available scoring system suitable for the study, and 
therefore constructed a scoring scale (Scandinavian Stroke Scale, SSS) adjusted to 
this study to be used by non-neurologists in general medical wards (40). This scale 
was routinely used at SUS before introducing the NIHSS scale in 2009. The SSS is 
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designed to give a score based on level of consciousness, eye movements, motoric 
function in the arm, hand, leg on the affected side and gait as well as orientation, 
speech and facial paralysis (Table 1.). The scale has good to excellent reliability and 
has been as well validated for retrospective use (41). 
 
  Scandinavian Stroke Scale (SSS)   
  Stroke scale item Score values 
1 Level of consciousness 0 - 6 
2 Eye movements 0 - 4 
3 Arm, motor power* 0 - 6 
4 Hand, motor power* 0 - 6 
5 Leg, motor power* 0 - 6 
6 Level of consciousness Questions 0 - 6 
7 Speech 0 - 10 
8 Facial palsy 0 - 2 
9 Walking 0 - 12 
  * Motor power is only assessed on the affected side Max. 58 
 
Table 1. Scandinavian Stroke Scale (SSS) 
 
1.6.2 NIHSS 
The NIHSS is a systematic assessment tool that provides a quantitative measure of 
stroke-related neurologic deficit (42). The scale is widely used as a clinical 
assessment tool to evaluate the deficiency in stroke patients, to determine appropriate 
treatment, and to predict patient outcome. The NIHSS is a 15-item neurologic 
examination stroke scale used to evaluate the effect of acute cerebral infarction on the 
levels of consciousness, language, neglect, visual-field loss, extraocular movement, 
motor strength, ataxia, dysarthria, and sensory loss (Table 2.).  NIHSS can be 
interconverted with SSS by using the following equation: SSS = 50 – 2 x NIHSS (Ali 
07) or SSS=50.37-1.63 * NIHSS (43) and has been shown to be equally good in 
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identifying 3 month outcome (44). The NIHSS is validated as an accurate tool for 
assessing stroke severity and is perceived as an excellent predictor for patient 
outcome with smaller NIHSS indicating smaller stroke lesion volume (45, 46).  
 
  Stroke scale item Score values 
1a Level of consciousness (LOC) 0 - 3 
1b Level of consciousness Questions 0 - 2 
1c Level of consciousness Commands 0 - 2 
2 Horizontal eye movement 0 - 2 
3 Visual field test 0 - 3 
4 Facial palsy 0 - 3 
5a Motor left arm 0 - 4 
5b Motor right arm 0 - 4 
6a Motor left leg 0 - 4 
6b Motor right leg 0 - 4 
7 Limb ataxia 0 - 2 
8 Sensory 0 - 2 
9 Language 0 - 3 
10 Dysarthria 0 - 2 
11 Neglect 0 - 2 
 
Table 2. National Institutes of Health Stroke Scale (NIHSS) 
 
1.6.3 Barthel Index 
The Barthel scale or Barthel ADL index (BI) is a widely used ordinal scale used to 
measure functional disability by ranking performance in activities of daily living 
(ADL). Each performance item is rated on this scale with a given number of points 
assigned to each level or ranking, maximum 100 points (47). It uses ten variables 
describing ADL and mobility (feeding, bathing, grooming, dressing, bowel 
control, bladder control, toileting, chair transfer, ambulation and stair climbing). 
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Today, the Barthel ADL-index used has the same parameters but the maximum score 
is 20 (Table 3.).  
 
  Activity Score Score 
1 Feeding 0 - 5 - 10 0 - 1 - 2 
2 Bathing 0 - 5 0 - 1 
3 Grooming 0 - 5 0 - 1 
4 Dressing 0 - 5 - 10 0 - 1 - 2 
5 Bowel control 0 - 5 - 10 0 - 1 - 2 
6 Bladder control 0 - 5 - 10 0 - 1 - 2 
7 Toileting 0 - 5 - 10 0 - 1 - 2 
8 Chair transfer 0 - 5 - 10 - 15 0 - 1 - 2 - 3 
9 Ambulation 0 - 5 - 10 - 15 0 - 1 - 2 - 3 
10 Stair climbing 0 - 5 - 10 0 - 1 - 2 
    0 - 100 0-20 
 
Table 3. Barthel Index, Activity, Scoring system at time of inclusion and today. 
 
1.7 Diagnostic tests 
In addition to the clinical neurological examination on admission, vital parameters as 
blood pressure, pulse and temperature are taken, neuroimaging by CT or MRI are 
done and supplementary tests including laboratory tests and electrocardiogram (ECG) 
are performed to assure the right diagnosis and to assess relevant comorbidity. 
Laboratory tests on admission included in the time the study was performed complete 
blood count, electrolytes, renal and liver function tests, blood glucose, markers of 
cardiac ischemia and coagulation status including international normalized ratio 
(INR) in the patients using warfarin. An ECG is performed to assess the heart rhythm 
and to identify cardiac comorbidity and arrhythmias.  Blood pressure is monitored 
and treated to ensure optimal cerebral perfusion, hyperthermia and infections are 
treated. Doppler ultrasonography is performed to evaluate precerebral vessel status. 
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1.7.1 Radiologic neuroimaging 
Diagnostic neuroimaging has undoubtedly a key role in the diagnosis of acute stroke. 
Primarily it is important to exclude acute hemorrhage, as it is a contraindication to 
intravenous thrombolysis. Radiological imaging by CT or MRI is also able to detect 
very early ischemia, and to quantify and discriminate irreversibly infarcted core tissue 
from salvageable penumbra and demonstrate areas of hemorrhagic transformation. 
Furthermore, large vessel occlusions can be diagnosed, in order to select patients for 
endovascular treatment.  
 
1.7.1.1 Computed tomography (CT) 
CT is the most commonly used initial imaging of acute stroke worldwide; it is 
quickly and easily accessible within most hospitals and provides sufficient 
information about stroke type, localization of the stroke and also about 
contraindications to treatment as intravenous thrombolysis. The scans can be 
performed with iodinated contrast injected in a peripheral vessel, for perfusion (CTP) 
and angiographic (CTA) scans that provide information about brain perfusion, 
penumbral tissue and vessel status.  
 
1.7.1.2 Magnetic resonance imaging (MRI) 
MRI is increasingly used in the diagnosis and management of stroke as it has a high 
sensitivity and specificity to detect ischemic changes (48). Yet, despite of increasing 
accessibility in the larger hospitals it is still not broadly used due to lacking routines, 
economic reasons and contraindications. Often MRI investigations are perceived as 
more time consuming and thus an initial CT investigation is preferred. In minor 
hospitals accessibility of MRI is the main challenge. Multimodal imaging protocols 
including diffusion-weighted series, perfusion imaging (MRP), FLAIR (fluid-
attenuated inversion recovery), mismatch calculations, T2* and intracranial 
angiography (MRA) results in accurate diagnostics for acute ischemic stroke patients. 
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1.7.2 Carotid ultrasound 
Carotid Doppler ultrasound is used to image the main precerebral vessels (the internal 
carotid artery and the vertebral artery) and to identify any disturbance of flow, 
velocity or structural lesions indicating stenosis and occlusions. Atherosclerotic 
carotid artery disease is an important risk factor for ischemic stroke and the risk of 
clinical symptoms increases with the degree of stenosis (49). The sensitivity and 
specificity for identifying a 50% stenosis and a >70% stenosis are 90-98% and 88-
94% respectively (50). The ultrasound procedure is less accurate than CTA and MRA 
but it is cheap, non-invasive and can be easily performed bedside.  
Stenoses are being measured according to different criteria locally and globally, as 
there exist no common consensus. The most common criteria are the North American 
Symptomatic Carotid Endarterectomy Trial (NASCET) criteria (51) and European 
Carotid Surgery Trial (ECST) criteria (52). In these trials the percentage of stenosis 
was calculated as a ratio of diameters measured from angiograms. The diameter of 
the residual lumen in the stenosis was compared with the diameter of the normal ICA 
lumen distal to the bulb in the NASCET method, as the ECST method compared it 
with an estimate of the diameter of the artery at the point of stenosis (Figure 1.). Both 
trials also showed the benefit of performing carotid endarterectomy in patients with 
significant ICA disease. The relationship between the ECST values and the NASCET 
values closely approximate: ECST+% = 0.6 NASCET % + 40 % (53). 
All ultrasound scanners use pulsed Doppler to measure the blood velocities measured 
as peak systolic velocity (PSV) and end-diastolic velocity (ESV). The PSV ratio has 
been widely used to assess the grade of stenosis. The ratio (PSVR) of peak systolic 
ICA velocity to peak systolic CCA velocity can be calculated. Peak systolic ICA to 
end-diastolic CCA ratio is called the St Mary’s Ratio. If these measurements are in 
agreement, diagnostic confidence is gained (Table 4.) (54-57). All velocities should 
be measured at a Doppler angle of 45-60°.  
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Figure 1. Diagram of ICA stenosis showing the NASCET and ECST methods of 














St Mary’s Ratio 














80–89 90 22-29 <50 
>90 (but less than
near occlusion)
95 >400 >5 >30 <30 
Near occlusion 
High, low – 
string flow 
Variable Variable 
Occlusion Occlusion No flow Not applicable Not applicable 
Table 4. Different Doppler grading systems for determing internal carotid stenosis 
(54-57). 
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1.8 Risk factors for stroke 
 
1.8.1 Age 
Age is the most important risk factor for stroke. The likelihood of having a stroke 
nearly doubles every 10 years after age 55. Although strokes are more common in the 
elderly, young people can suffer a stroke as well. In a review by Appelroos and 
colleagues with over 30 000 patients in 19 countries, the mean age at first stroke was 
68.8 years for men (variations from 60.8 years in Ukraine to 75.3 years in Norway) 
and 72.9 years for women (65.3 in Malta to 80.4 in Sweden) (58). In Norway, the 
mean age at stroke in 2015 was 75 years (77.5 years for women and 71.9 years for 
men), and 90% of the stroke patients were >60 years old (18).  
 
1.8.2 Sex  
Women have a higher lifetime risk of stroke than men. In the Framingham Health 
Study (FHS), lifetime risk of stroke among those 55-75 years of age was 1 in 5 for 
women and 1 in 6 for men (24). This difference is explained by longer life 
expectancy for women. The age-specific incidence rates are substantially lower in 
women in the younger and middle-age groups. As most strokes occur in the higher 
age groups the longer life expectancy is leveling out this effect, leading to overall 
incidence rates in women that are approximately equal to or even higher than those in 
men (58-60). The stroke mortality for women in general is generally higher than for 
men. This is again caused by an age effect due to higher life expectancy in women. In 
the age group <85 years more men are dying of a stroke (26, 59). 
Female-specific risk factors for stroke include: Pregnancy, history of preeclampsia/ 
eclampsia or gestational diabetes (61), oral contraceptive use (especially when 
combined with smoking and migraine with aura) (62), post-menopausal hormone 
therapy (63) and oophorectomy (64). Preeclampsia is associated with increased stroke 
 28 
risk and may be mediated by later risk of hypertension and diabetes mellitus (DM) 
(65), also genetic factors play a role (66).  
 
1.8.3 Hypertension 
Long term hypertension (defined as a systolic blood pressure ≥140 mmHg and/or a 
diastolic pressure ≥90 mmHg) is the leading cause of stroke and the most significant 
controllable risk factor for stroke (67-69). The pathogenesis of hypertension is 
conceived as multifactorial: genetic, environmental and behavioral factors are 
interplaying. Antihypertensive treatment is effective for all age groups and races and 
is decreasing stroke risk and the risk of other cardiovascular events. In a large meta-
analysis by Law and colleagues a 41% (33% to 48%) risk reduction in stroke when 
reducing systolic blood pressure with 10 mm Hg systolic or diastolic blood pressure 
with 5 mm Hg was confirmed (70). This evidence is supported by other studies 
concluding that intensive blood pressure (BP) control (systolic blood pressure (SBP) 
<120mmHg) results in a significantly lower risk of stroke, less recurrent strokes and 
minor cardiovascular events in general (71-73). It is recommended that blood 
pressure should be lower than 130/80mmHg, especially in people at high risk of 
stroke (74).  
 
1.8.4 Smoking/Tobacco use 
Cigarette smoking is a substantial risk factor for ischemic stroke and (75, 76), with a 
dose-response relationship between smoking and risk of stroke across age groups 
(77). The nicotine and carbon monoxide in cigarette smoke damage the 
cardiovascular system and increases the stroke risk equally for men and women (77). 
Cigarette smoking combined with use of oral contraceptives can greatly increase the 
risk of stroke (78), as also smoking combined with hypertension (79). Even passive 
smoking is proved to be a dose-responsive risk factor for stroke and thus all smoking 
stroke patients should be encouraged to quit smoking (80). 
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1.8.5 Diabetes mellitus  
Diabetes mellitus (DM) is an independent risk factor for stroke. As many people with 
diabetes also have other risk factors as high blood pressure, high blood cholesterol or 
overweight, the cumulative risk factors elevate stroke risk even further. Diabetes 
mellitus increases ischemic stroke risk at all ages, but the risk is most prominent 
before 65 years (81).  Diabetes mellitus more than doubles the risk for stroke, and it is 
estimated that almost 20% of patients with diabetes mellitus will die of a stroke. 
Several mechanisms are hypothesized, including direct neurotoxicity and systemic 
consequences (82, 83). The duration of diabetes mellitus is associated with the 
cumulative stroke risk and it is estimated that the stroke risk increases by 3% each 
year of diabetes duration (81). In case of prediabetes, fasting hyperglycemia is 
associated with stroke (84).  
For patients with diabetes mellitus multifactorial treatment can decrease stroke risk 
significantly (85). In patients with DM type 2, there is no evidence that reduced 
glycaemia decreases the short-term risk of macrovascular events, including stroke 
(86). A glycated hemoglobin goal of <7.0% has been recommended by the American 
Diabetes Association to prevent long-term microangiopathic complications, but the 
impact on long-term risk of stroke is unclear. A meta-analysis by Zhang showed that 
intensive control of glucose compared with usual care had no effect on incident 
stroke but in a stratified analyses, a beneficial effect was seen in patients with 
diabetes mellitus and a body mas index (BMI) >30 kg/m
2
 (87). Aggressive BP 
lowering in patients with diabetes mellitus and hypertension reduces stroke incidence 
in all age groups (88). 
 
1.8.6 Atrial Fibrillation  
Atrial fibrillation (AF), an arrhythmic heart rhythm characterized by rapid and 
irregular beating is associated with a 4- to 5-fold increased risk of ischemic stroke. 
The lack of organized atrial contraction can lead to stagnation of blood in the left 
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atrium or left atrial appendage (LAA). Through thrombus formation and thrombus 
mobilization these blood clots can be spilt away with the blood flow, causing emboli 
leading to TIA or stroke (89). It is assumed that AF is common and underestimated in 
patients with cryptogenic stroke (90), and screening for arrhythmias is therefore 
recommended in this patient group (91, 92).  
 
1.8.7 Heredity/family history 
A documented parental ischemic stroke is associated with a 3-fold increased stroke 
risk in offspring also after adjustment for other known stroke risk factors (93), and 
parental history of several other CVDs increase the risk for new CVDs (27, 94). The 
gene regions/genes found to be important, are involved in a variety of different 
functions related to atherosclerosis, coronary artery disease, atrial fibrillation, blood 
pressure, coagulation, carotid plaque formation and neuroinflammation i.a. (35). 
Certain stroke subtypes have higher estimated heritability to certain gene loci 
according to genome-wide association studies. For large-vessel disease robust 
association have been reported with gene loci HDAC9 and TSPAN2 (95-97), for 
cardioembolic stroke PTX2 and ZFHX3 (97, 98) and for small-vessel disease FOXF2 
(99); Apoprotein E alleles are also clearly  associated with ICH (100). A trend is 
emerging toward higher heritability in women and younger stroke patients (98, 101).  
 
1.8.8 Hypercholesterolemia 
Hypercholesterolemia, also called dyslipidemia, is the presence of high levels of 
cholesterol or blood lipids. Lipoproteins transports the cholesterol particles, and are 
classified by their density: very low density lipoprotein (VLDL), low density 
lipoprotein (LDL), intermediate density lipoprotein (IDL) and high density 
lipoprotein (HDL) (102). Elevated levels of the lipoproteins other than HDL (termed 
non-HDL cholesterol) and LDL in the blood may be a consequence of diet, obesity, 
inherited (genetic) diseases (such as LDL receptor mutations in familial 
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hypercholesterolemia), or the presence of other diseases such as diabetes or an 
underactive thyroid (103). Elevated levels of particularly LDL-cholesterol are 
associated with an increased risk of atherosclerosis, coronary heart disease (104) and 
stroke (105). In contrast, higher levels of HDL cholesterol are protective and elevated 
total cholesterol is inversely associated with hemorrhagic stroke (106). Statin therapy 
reducing LDL-cholesterol can safely reduce the 5-year incidence of major coronary 
events, coronary revascularization, and stroke by about one fifth per mmol/L 
reduction in LDL cholesterol (107). This effect is largely irrespective of the initial 
lipid profile or other presenting characteristics (108). However, the association of 
each subfraction has shown inconsistent results on ischemic and hemorrhagic stroke 
risk (105, 109-112) and several studies consider the fortunate effect of statins not 
being caused by its cholesterol lowering properties (113). 
 
1.8.9 Carotid stenosis 
The precerebral carotid vessels, most importantly the common carotid artery and 
internal carotid artery supply the brain with blood. These vessels and especially the 
carotid bifurcation are common sites for atherosclerosis due to increased turbulence 
and areas of lower shear force (114) which gives room for an inflammatory buildup 
of an atheromatous plaque that narrows the lumen and influences the blood flow. The 
plaque can be stable and asymptomatic or it can be a source of embolization. The 
correlation between severity of stenosis and ischemic events is not perfect, and 
molecular and cellular processes responsible for plaque composition might be more 
important for the risk of stroke. Thickening of the internal artery layer (the intima 
media) is the first sign of subclinical atherosclerosis, and the inflammatory process of 
atherosclerosis is shown to be most prominent at the early stages (115).  
Calcification, incidence of lipid core and fibrous cap and intraplaque hemorrhage are 
characteristics that determine plaque stability (116, 117). Large resultant plaques 
extruding into the vessel lumen pose not only an impedance to flow but serve as a 
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nidus for thrombus formation. In addition, plaque instability and plaque rupture can 
propagate thromboembolic debris and lead to cerebrovascular events. 
The Framingham Heart Study noted a prevalence of significant (>50%) carotid 
stenosis of 7% in woman and 9% in males ranging between 66–93 years (118). 
Atherosclerotic carotid artery disease is an important risk factor for ischemic stroke 
and the risk of clinical symptoms increases with the degree of narrowing (49), which 
can be measured by duplex ultrasound. The sensitivity and specificity for identifying 
a 50% stenosis and a >70% stenosis is high, 90-98% and 88-94% respectively (50). 
There exist various grading criteria; the most common used being the NASCET and 
ESCT (91, 91) criteria (1.7.2 Carotid ultrasound).  In the Asymptomatic Carotid 
Stenosis Risk Stratification study (ACSRS), the risk of stroke increased from 0.6% 
per year in patients with mild stenosis (50%–69%) to 1.9% per year in patients with 
severe stenosis (≥ 90%) (119). An increase in the degree of stenosis by 2 or 3 
categories (50%–69%; 70%–89%; 90%–99%; and 100%) over 1 year was related to 
an increase in the incidence of ipsilateral ischemic events by a factor of 4 or 7, 
respectively (120). Some plaque features as echolucency, intraplaque hemorrhage and 
a thin fibrous cap are associated with significantly higher stroke risk (121). The 
stroke risk of carotid stenosis is enhanced if other risk factors as hypertension, 
smoking or diabetes coexist (27). Carotid stenosis ≥25% is also associated with a 2.2-
fold increased risk of cerebral microbleeds (122). Roughly, carotid stenoses can be 
graded in mild (<50%), moderate (50 - 79 %), severe (80 – 99%) stenosis and 
subtotal/total occlusion (100%). 
 
1.8.10 Hyperhomocysteinemia 
A high level of the non-protein α-amino acid homocysteine in the blood (≥15,0 
umol/L) (hyperhomocysteinemia) makes the cells more prone to endothelial injury. 
This can lead to inflammation in the blood vessels, which in turn can lead to 
atherogenesis and can result in ischemic injury (123). Hyperhomocysteinemia is 
thereby a known risk factor for stroke (124), but its relevance is debated. Smaller 
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studies have shown that elevated homocysteine (HCY) promotes cerebral, arterial, 
and venous thrombosis and may predispose to premature atherosclerosis, 
craniocervical arterial dissection (125), increased oxidative stress (126) and can be 
assessed with long-term mortality (127). Even though hyperhomocysteinemia is 
generally acknowledged as a treatable risk factor for atherotrombotic diseases and 
stroke, the current guidelines (128) do not recommend routine screening. 
 
1.8.11 Renal impairment  
It is known that chronic kidney disease is a risk factor for stroke (129). A meta-
analysis of >280 000 patients showed a 43% increased incident stroke risk among 
patients with a glomerular filtration ratio (GFR) <60 mL/min (130), which is 
confirmed in other studies (131). Although GFR is routinely measured in clinical 
practice, proteinuria and albuminuria are better predictors of stroke risk in patients 
with manifest kidney disease (132). As subtle renal impairment (high normal serum 
creatinine) is a marker of increased cerebrovascular disease risk (133) and is 
associated with other relevant prognostic risk factors (hypertension, age, diabetes, 
heart failure), leading to the claim that renal impairment should be included in 
cerebrovascular risk scores (134). Renal impairment before suffering a stroke is also 
associated with worse clinical outcome (135). 
 
1.8.12 Inflammation 
Proinflammatory conditions, including acute and chronic infections, have been 
associated with an increased stroke risk. The risk of stroke is increased both in the 
acute and in the chronic phase of a wide spectrum of inflammatory conditions, and it 
is suggested that the inflammatory response rather than the condition itself is 
responsible for the increased risk (136). Different inflammatory mechanisms are 
deemed to play a role in the different stroke subtypes. This hypothesis is based on the 
observation that high levels of various immune system markers and acute phase 
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reactants in otherwise healthy individuals have been associated with stroke subtypes. 
C-reactive protein, IL-6, and lipoprotein-associated phospholipase A2 are some of the 
inflammatory markers that have been linked to stroke risk and prognosis (136). 
Multiple epidemiological studies have demonstrated that these markers are associated 
with increased risk of stroke, but the value of these markers in a clinical setting has 
not yet been proven. 
 
1.8.13 Anemia 
Anemia, a decrease of red blood cells or hemoglobin in the blood seems to have a 
clear association with cerebrovascular events. On one hand there is a direct 
connection between blood supply and tissue oxygen delivery, on the other hand there 
seems to be a link between anemia and new onset atrial fibrillation (137). Yet, anemia 
independently increases the risk of thromboembolic events as it is considered a 
hyperkinetic state which disturbs endothelial adhesion molecules that may lead to 
thrombus formation. Furthermore, blood flow augmentation and turbulence may 
result in the migration of a thrombus thus facilitating artery-to-artery embolism (138). 
Anemia on admission increases mortality and decreases functional improvement 
through increase of complications impeding stroke rehabilitation (139, 140). 
Furthermore, reduced blood hemoglobin levels impair oxygen delivery to the brain 
and hinder neurological improvement. Reduced blood hemoglobin level is a predictor 
of short and long-term mortality after stroke (141). Anemia due to the genetic 
disorder sickle cell anemia is a risk factor for strokes, especially in children and 
young patients (142, 143). 
 
1.8.14 Other risk factors  
Other risk factors influencing stroke risk not discussed here are core health behavior 
as physical inactivity, nutrition and obesity. In addition, medical conditions as sleep 
apnea and metabolic syndrome, as well as different psychosocial factors are possible 
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risk factors, increasing stroke risk especially when combined with any other risk 
factors (27).  
 
1.9 Stroke treatment  
 
1.9.1 Acute stroke treatment 
Today, acute treatment of ischemic stroke means earliest possible reperfusion of the 
occluded artery accompanied by general supportive care and treatment of acute 
complications.  
In 1995 there was a paradigm shift when intravenous thrombolysis (IVT) with rt-PA 
was introduced and occlusions could be treated effectively (144). Prior to this, the 
treatment was mainly supportive. IVT is considered as safe and effective treatment 
when administered within 4.5 hours after symptom onset (145, 146). Endovascular 
treatment (EVT) with mechanical intra-arterial thrombectomy should be administered 
in case of large vessel occlusions (147, 148).  
 
1.9.2 Supportive stroke treatment 
General supportive care is provided for all stroke patients, independently of treatment 
with IVT or EVT (149). Generally, it is strongly recommended that all stroke patients 
are treated in specialized stroke centers (150) as this enhances functional outcome for 
all patients. According to current AHA guidelines (151) and national guidelines (152) 
the following factors are in focus:  
Hypoxia: Treatment with supplementary oxygen is provided when the oxygen 
saturation is below 95% (153).   
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Circulation: The blood pressure (BP) is optimized to ensure adequate blood flow and 
oxygen deliverance to the brain (154), and is lowered when BP is >220/120mmHg. In 
patients retrieving intravenous thrombolysis or endovascular treatment blood pressure 
below 185/110mmHg is recommended. In case of ICH, the current recommendations 
are that the systolic BP should be <180mmHg (155), but intense treatment to secure 
systolic BT <140mmHg seems to be safe (155). Hypovolemia and blood glucose are 
monitored and quickly corrected with intravenous fluids and insulin or glucose as 
needed (156). Both hypo- and hyperglycemia at acute stroke predict poor outcome 
(157, 158) and should be avoided. 
Heart function: Electrocardiogram (ECG) is performed for detection of atrial 
fibrillation or other potentially serious cardiac arrhythmias that might need 
emergency therapy. 
Hyperthermia: is associated with poor outcome (159) and body temperature should be 
lowered.  
 
1.9.3 Secondary stroke prevention 
Depending on the cause of the stroke, secondary prevention treatment with 
medication is recommended for most patients. Life-long antithrombotic medication 
and cholesterol lowering statins are recommended for most patients, in addition to 
antihypertensive and antidiabetic medication if needed. For patients with cardio-
embolic strokes, anticoagulation therapy is indicated, and for ICH blood-thinning 
medication is contradicted in most cases (152, 160). Initiation or optimization of BP 
therapy is indicated in stroke patients where the BP is not falling spontaneously ≤140 
mm Hg systolic or ≤90 mm Hg diastolic during the first days. Although these BP 
values are given as a reference the individual BP goals in each patient and the level of 
reduction from pretreatment baseline values remain uncertain and should be 
individualized (128). For all patients, general lifestyle advice and changes are 
recommended, i.e. smoking cessation, increasing daily physical activity, weight 
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reduction, healthy low-sodium diet and avoidance of excessive alcohol intake – all of 
which alone or combined reduce the risk for recurrent strokes or CVD (161-166).  
 
1.9.3.1 Antithrombotic medication 
In patients with a non-cardioembolic stroke or TIA antiplatelet drugs are 
recommended. There are three approved antithrombotic drugs in Norway: Aspirin, 
combination aspirin/dipyridamole and clopidogrel); on average, these agents reduce 
the relative risk (RR) of stroke, myocardial infarction (MI), or death by ~22% (128, 
167). In patients with non-valvular atrial fibrillation whether paroxysmal or 
permanent, oral anticoagulants are the first choice, either VKA or direct oral 
anticoagulants (DOAC) as apixaban/dabigatran/rivaroxaban/edoxaban (128).  
 
1.9.3.2 Statins  
Blood cholesterol is effectively lowered by daily use of oral 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). Statin therapy 
is recommended to reduce the risk of stroke and cardiovascular events among patients 
with ischemic stroke or TIA. The statin effect is assumed to be most notable in case 
of atherosclerotic disease with embolization from carotid or aortic vessels (107, 128). 
The Norwegian national guidelines recommend statin treatment if LDL cholesterol is 
>2.0mmol/l (152). Stroke patients already using statins at admission have better 
outcome and lower mortality (168). As the SPARCL trial revealed, achieving a LDL 
cholesterol level of <70 mg/dL (1.8mmol/l) by using statins was related to a 28% 
reduction in risk of stroke without a significant increase in the risk of hemorrhagic 
stroke. Additionally, stroke and TIA patients with ≥50% reduction in LDL 
cholesterol had a 35% reduction in combined risk of nonfatal and fatal stroke (169). 
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1.10 Mortality  
A decline in stroke mortality and morbidity over the past decades is seen in all age 
groups, for both sexes, and for all racial/ethnic groups. It mirrors the achievements in 
acute stroke therapy, diagnostics and rehabilitation. These achievements are of major 
importance for global health, and entail a huge economic potential. The decline in 
mortality results from reduced incidence of stroke and lower case-fatality rates 
combined. This happened concurrent with cardiovascular risk factor control 
interventions. Although it appears to be difficult to credit a specific risk factor 
control, efforts in hypertension control initiated in the 1970s appear to have had the 
most substantial influence on the accelerated decline in stroke mortality (29). 
Although implemented later, diabetes mellitus and dyslipidemia control in addition to 
smoking cessation programs, particularly in combination with treatment of 
hypertension, also appear to have contributed to the decline in stroke mortality. 
The mortality after stroke increases generally with higher age and after recurrent 
strokes. Thus, the stroke mortality is in general higher for women due to older age at 
stroke (59). In the lower age group (<85 years) the mortality is higher for men (26). 
Hemorrhagic strokes are associated with higher mortality and morbidity as compared 
to ischemic strokes, although they are in total less common (6).  
Data from the Atherosclerosis Risk in Communities (ARIC) study showed that the 
cumulative all-cause mortality rate after a stroke was 10.5% at 30 days, 21.2% at 1 
year, 39.8% at 5 years, and 58.4% at the end of the 24 years of follow-up (112). 
Mortality rates were higher after an incident hemorrhagic stroke (67.9%) than after an 
ischemic stroke (57.4%). Age-adjusted mortality after an incident stroke decreased 
over time (absolute decrease of 8.1 deaths per 100 strokes after 10 years), which was 
mainly attributed to the decrease in mortality among those aged ≤65 years (absolute 
decrease of 14.2 deaths per 100 strokes after 10 years) (170, 171).  
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1.11 Nursing home placement after stroke 
Stroke is the single most important factor for complex disability in adults (172) and 
therewith as well the main cause for nursing home placement (NHP) (172-174). In 
2010, 39.4 million DALYs were lost because of ischemic stroke and 62.8 million 
because of hemorrhagic stroke (64% and 85%, respectively (175)). After a stroke, 
roughly two-thirds of the patients are consequently disabled in some way (176). 
About half of the surviving stroke patients can be directly discharged from hospital to 
their homes; the other half has a remaining disability requiring special services or 
even institutionalized care (173, 177-179). Yet, reported institutionalization rates 
after stroke vary widely by population, setting, and duration of follow-up: 13 - 45% 
of stroke patients are institutionalized directly after hospitalization (177, 180, 181) 
and 10 - 83% within a period of 5 years (15, 23, 178, 182, 183). Age and initial stroke 
severity are the main predictors for NHP after stroke (180, 184-186), as well as age, 
cognitive and functional impairment that are the main predictors in the general 












2. Aims of the study 
 
2.1 Paper I 
Statin therapy has an established role in the treatment of atherosclerotic disease and 
in secondary stroke prevention, and is especially important in carotid stenosis. The 
aim was to analyse the effect of statin treatment on long-term survival, by analysing 
the long-term survival rates and the causes of deaths of patients with carotid artery 
stenosis on statin treatment compared to matched statin naïve patients.  
 
2.2 Paper II 
Stroke is one of the leading causes of mortality worldwide, and understanding the risk 
factors associated with long-term stroke mortality is important. The aims were to 
compare long-term mortality of patients with acute stroke compared to a 
geographically age- and sex-matched, stroke-free control. We aimed to identify 
possible risk factors for long-term mortality in the stroke patient group.  
 
2.3 Paper III 
Stroke is one of the leading causes for NHP, but the prognosis of NHP for the 
patients that can be discharged home after stroke is not known. The aims in study 
three were to analyse the proportion of stroke patients that could initially be 
discharged home, and to further analyse the need for NHP in this group compared to 
a matched stroke free control group. Additionally, we aimed to assess risk factors for 
permanent NHP. 
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3. Subjects and methods 
 
3.1 Patients and follow up  
The Stavanger University Hospital (SUS) serves the county of Rogaland with a 
population of approximately 330 000 inhabitants, distributed between 29 smaller 
municipalities at the time of inclusion. The municipality of Stavanger was the largest 
with approximately 130 000 inhabitants. All study participants in paper one were 
referred consecutively as outpatients to the cerebrovascular ultrasound laboratory 
between 1994 to1996. The patients were followed until death or the end of the 
observational period on May 1
st
, 2011.   
All patients consecutively admitted to the stroke unit at SUS between January 1, 1996 
and March 31, 2004 were included in the study in paper two (n=1472). These patients 
were followed until death or until May 31, 2012. All patients belonging to the 
municipality of Stavanger from this cohort were studied further regarding NHP in 
paper three (n=452), and were followed until death or until May 31, 2012. 
 
3.2 Controls 
The control group in study two and three was obtained from the National Population 
Register of Statistics in Norway. Reference individuals were acquired arbitrarily from 
the general population but were individually matched 1:1 according to sex, age and 
local residency on the same year the patient was hospitalized for stroke. To have a 
stroke-free control group the hospital files for the control individuals were examined 
for stroke diagnoses. Individuals with a stroke or a transient ischemic attack (TIA) 
diagnosis (431, 434, 435 in ICD-8 and ICD-9, I61 and I63 with subclasses in ICD-10) 
were excluded from the control group along with their corresponding index patient. 
No clinical data was available for the control group.  
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3.3 Ethics 
The studies were conducted in accordance with the Declaration of Helsinki. All 
studies were approved by the Regional Ethics Committee for Medical Research 
Ethics, University of Bergen.  
 
3.4 Clinical evaluation 
The patients in paper 1 were examined with an ultrasound procedure at their first 
visit. At this baseline examination demographic and clinical data from the 
participants were collected and a cholesterol measurement was done. The ultrasound 
procedure is described below. 
For the patients in paper two and three, a neurologic examination including SSS (40) 
was performed at admission as well as diagnostic neuroimaging with a CT scan. Data 
on patient`s functional status before and after the stroke (Barthel Index) were 
assembled by stroke nurses in collaboration with the patient and their families (47). 
Data regarding occupation, marital status and residency at the time of stroke were 
complied. Pre-existing cardiovascular disease, hypertension, smoking, diabetes, 
heredity for cardiovascular disease and blood pressure on admission were also noted. 
The index stroke type was further classified into cerebral infarction, intracerebral 
hemorrhage or TIA. 
   
3.5 Laboratory analyses 
For study two and three routine hematological analyses were performed at admission 
including hemoglobin, leucocytes, creatinine, electrolytes, CRP and INR.  The first 
day after admission, fasting glucose and cholesterol, HDL cholesterol, LDL 
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For study two and three an electrocardiogram was performed at admission in all 
patients to identify cardiac pathology or arrhythmias such as atrial fibrillation. 
 
3.7 Ultrasound Doppler 
All sonographic examinations were performed by the same, experienced neurologist 
using a EME/Nicolet 2000 TC 2020 Doppler device with a transducer with 2 and 4 
MHz frequencies in pulsed and continuous wave Doppler modes for complete 
peripheral vascular applications. All velocities were measured at a Doppler angle of 
45-60%. The degree of stenosis was calculated by the peak systolic velocity ratio (54, 
189). 
 
3.8 Nursing home placement  
In the city of Stavanger which is the largest municipality in the region with about 
130 000 inhabitants, a digital register (“CosDoc”) exists, containing complete 
information regarding temporary and permanent nursing home placement (NHP). 
Reliable information about NHP was to a large part lacking in the other 
municipalities in the region, and thus we only included patients registered in the city 
of Stavanger at the time of their stroke along with their matched controls. As there 
existed several different types of rehabilitation settings and temporary nursing home 
placements, we have only recorded the dates for permanent nursing home placement.  
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3.9 Statistical analysis 
The basic statistical analyses were performed in IBM SPSS 18.0 and 22.0 (SPSS Inc, 
Chicago, IL, USA) and in R.  Chi-squared test was used for categorical variables and 
one-way analysis of variance (ANOVA) to compare means for continuous variables. 
For survival analysis Kaplan-Meier curves were calculated and logistic regression 
analysis was used to assess the impact of risk factors affecting time until NHP. 
Kaplan-Meier plots illustrate the observed survival in patients and controls.  
In paper two, Chi-squared tests were used to compare the survivor fraction between 
both groups at different time points. A shared frailty model was fitted in R (package 
survival, function coxph for Cox regression) to compare overall mortality between 
the stroke patients and their matched controls. The analysis of risk factors for death 
among stroke survivors, was also performed using coxph.  All continuous variables 
were standardized before the analysis, and covariates contributing little to the fit of 
the model were removed from the model. The effects of predictors with evident non-
linear effects were modelled by multivariable fractional polynomials using the 
package mfp. The proportional hazards assumption was tested by examination of 
Schoenfeld residuals by function cox.zph. Models were compared by likelihood ratio 
tests. All excluded variables were reintroduced into the final model to check for 
confounding effects.  





4.1 Paper I 
The study showed a markedly increased long-term survival among patients with 
carotid stenosis taking statins compared to statin-naïve patients, also after controlling 
for age and cholesterol-levels at baseline. The effect was long-lasting and had a 
persistent increase over time. The causes of deaths were nearly identical in both 
groups; thus we hypothesize that the increased survival is caused by more general 
statin effects than due to a reduction of vascular risk factors. 
 
4.2 Paper II 
In this study, we followed stroke patients surviving the first year after acute stroke for 
up to 16.4 years. We compared their mortality risk with a matched, stroke free control 
group. At the end of the study period, 51.7% of the patients and 32.7% of the stroke 
free control individuals had died (HR of 2.2 (CI 1.9 – 2.5) (p<0.001)). The mortality 
risk stayed continually increased for at least 10 years. Regression analyses indicated 
that in addition to the known risk factors age, diabetes, and stroke severity also low 
cholesterol and hemoglobin as well as elevated creatinine and homocysteine at index 
stroke were associated with increased long-term mortality. These factors are 
modifiable and should possibly be followed more intensely after patient dismissal. 
 
4.3 Paper III 
In this study, we show that the majority of our stroke patients (88.7%) were able to 
live at home either directly after their stroke or after initial short-term rehabilitation. 
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Yet, stroke patients discharged to their homes needed NHP significantly more 
frequently and earlier than the stroke free, age and sex matched control population 
from the same geographical area (29.9% vs 18.5%). After initial hospital discharge, 
only age was a risk factor for NHP. The length of the stay in the nursing home 
facilities did not differ compared to non-stroke controls. Both groups stayed less than 




















Stroke affects about 17 million people each year globally, a number projected to 
increase because of demographic changes and an aging population where the risk of 
stroke is greatest.  
The Global Burden of Disease study has calculated that between 1990 and 2010 
despite of falling age-standardized rates of incident stroke, the number of strokes 
occurring worldwide increased by 68% and the number of stroke survivors by 84% 
(31). This increase in stroke prevalence is caused by improvements in acute stroke 
care such as organized inpatient stroke unit-based care (29) and the implementation 
of IVT and EVT leading to a greater proportion of patients surviving the acute stroke 
episode (31). As treatment of stroke patients improves continuously, long term 
follow-up studies of stroke patients acknowledge the fact that treatment conditions 
have changed during the observational period. This is the case for the patients 
included in our studies as well. 
In present not only more patients survive their strokes, but they survive with fewer 
handicaps, leading to improved survival and increased prevalence of stroke. As 
consequence of this increased survival stroke survivors and their families have to deal 
with the long-term consequences of stroke, including physical disability, cognitive 
impairment (190), fatigue, and psychological problems such as depression and 
anxiety. Stroke is shifting away from being a major killer to become a long-term 
(chronic) condition with multiple impacts for individuals, health systems and society 
(31, 191). Therefore, research regarding long-term consequences of stroke is of 
utmost interest. However, although data about long term follow up are emerging 
increasingly, most studies have a relatively short follow-up.  
In the papers included in this thesis we have focused on long-term survival and risk 
factors that influence mortality over time in both stroke survivors and in patients with 
carotid stenosis. We have compared stroke patients to matched, stroke-free controls 
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from the general population. In the following chapters the papers are discussed one 
by one. 
 
5.1 Paper I  
 
5.1.1 Mortality 
In the first paper, we analyzed whether statin use prolongs survival in patients with 
carotid stenosis. This is of special interest as statin use has shown to decrease stroke 
rates in patients with general atherosclerosis and especially patients with carotid 
stenosis (192-194). We could show that statin use in patients with carotid stenosis 
was, independently of preexistent cholesterol levels, associated with increased 
survival (88.3% of the patients that never used statin had died, compared to only 
39.6% in the statin group, p<0.001). The difference in mortality remained highly 
significant over time also after adjusting for age and current smoking. Yet, statin use 
did not influence the causes of death and did not reduce the proportion of vascular 
causes of death. This could indicate that the extended survival of statin users could be 
explained by other, more general effects of statins. These results are consistent with 
other studies (113). The statin effect on mortality in our study was long-lasting (> 10 
years) and showed a persistent increase over time. This indicates possible benefits of 
statin treatment beyond today’s knowledge and extended use for a wider patient 
group should be investigated. However, our results are limited by the fact that 
treatment stratification was not performed by random and confounding by indication 
cannot be excluded, although the study team did not influence the decision to start 
statin treatment during baseline examination or follow-up. Yet, this kind of study 
could not have been done today, because present guidelines strongly recommend 
statin use when atherosclerosis is documented or lipid measurements exceed certain 
values (128, 195), especially in patients with carotid stenosis (196). The guidelines 
were not as rigorous at the time of patient inclusion and the use of statins was not 
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mandatory.  In earlier conducted studies in the same study population the use of statin 
medication (simvastatin) was shown to prevent progression of carotid artery stenosis, 
and maybe even reverse stenosis grade (197, 198). In other studies, in patients with 
moderate to severe carotid stenosis, optimal medical treatment including statin 
treatment failed to reverse stenosis grade and in some studies as well no effect on 
disease progression was seen (199, 200). Different effects of statin medication on 
carotid stenosis may be based on different pathophysiological processes ongoing in 
different stenosis grades, inflammatory ones being more pronounced in the early 
stages. Carotid stenosis leading to transient or permanent neurologic or retinal 
symptoms within the preceding 6 months are deemed symptomatic and require 
prompt noninvasive evaluation and treatment (195, 201). Landmark trials have 
proven carotid endarterectomy (CEA) superior to medical therapy for stroke 
prevention in symptomatic lesions. Carotid artery stenting (CAS) is found to be non-
inferior to CEA, and the strength of the combined data has led to a class I 
recommendation for CEA or CAS in patients with high grade symptomatic carotid 
stenosis, provided the risk of perioperative events is acceptable (195, 202). In our 
study, the patients with ICA occlusion or symptomatic lesion were excluded.  
Our results show that statin treatment in patients with carotid stenosis led to 
significantly increased survival, independently of their preexistent cholesterol levels.  
Surprisingly, we did not see a decline in cardiovascular related deaths which adds 
evidence to the present belief that rather “pleiotrophic than cholesterol-lowering 
effects” are contributing. “Pleiotrophic effects” discussed to contribute are effects on 
endothelial function, cell proliferation, inflammatory response, immunological 
reactions, platelet function, and lipid oxidation. These "pleiotropic actions" are 
independent of the cholesterol lowering ones, and appear to be neuroprotective (113, 
203). Fitting to this concept statin use has shown to be beneficial as in sepsis (204), 
cerebral hemorrhages (205), carotid surgery (202) and possibly also as add-on 
treatment in depression as well (206).  
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5.2 Paper II 
 
5.2.1 Long-term mortality 
Most studies investigating long-term consequences of stroke include data from the 
first month after dismissal and thereby mix short-term and long-term consequences. 
To be able to analyze only the long-term mortality of initial stroke survivors we did 
not include patients dying within the first year after their stroke. Previous studies 
about long-term mortality in stroke patients are limited by the fact that they have a 
relatively short observational period. There are not many studies reporting 5-10 years 
outcome (15, 207, 208) and those few with more than 10 years of follow-up have 
only small numbers of included patients (209-211).  
We followed stroke patients that survived the first year for up to 16.4 years, and 
compared them to an age- and sex matched stroke-free control group. The mean age 
at stroke was 66.8 years. At the end of the study, 51.7% of all patients had died 
compared to 32.7% of the stroke free controls (Risk Ratio (RR) 1.58 (CI 1.43 – 1.75, 
p<0.001)). The follow up time of the included stroke patients differed substantially 
due to varying inclusion times and time points of deaths: After 5 years follow 
up57.3% of the patients had died compared to 37.4% of the stroke free controls. After 
12 years the corresponding numbers were 72.5% for stroke patients and 53% for 
controls. Thus, our mortality numbers are in line with earlier conducted studies where 
the cumulative case fatality was estimated around 40% to 60% 5 years (212-214) and 
>80% 14 years after acute stroke (215, 216).  
 
5.2.2 Risk factors 
The risk of death is greatest in the first few weeks after the stroke. The resulting brain 
injury and secondary complications, partly due to immobilization, are believed to be 
the main causes for the short-term mortality (217-219). Risk factors predicting long-
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term mortality in stroke patients have been less understood (211, 220), but there is 
evidence that other factors are of importance in predicting long term mortality. The 
most important risk factor for mortality after stroke, early and late, is undoubtedly 
age (29). For early mortality (within the first year) the severity of the stroke and 
cardiovascular risk factors such as atrial fibrillation (217, 221) are prominent risk 
factors. For long-term mortality smoking, male gender and diabetes have been 
postulated as risk factors (159, 222, 223).  
In our study age, diabetes and stroke severity predicts mortality in stroke survivors 
also in the long run. Yet, atrial fibrillation, previous stroke and hemorrhagic stroke 
were not significant. In our study, relatively few patients with atrial fibrillation and 
hemorrhagic stroke were included, thus the lack of statistical significance should not 
be overrated. Atrial fibrillation, often underdiagnosed and asymptomatic, is an 
independent risk factor and is thought to generate new strokes and thus increase the 
ischemic burden (224, 225). The same mechanism is discussed for patients with 
earlier strokes of other etiology and for the aging brain: Decreasing functional 
capacity of the brain and increasing burden of the disease lead to functional decline 
(226) and increase risk of mortality (227).  
Diabetes is shown to be a predictor of increased mortality in stroke (228). The 
mechanism is thought to be microangiopathic, leading to small vessel disease. 
Diabetes is also associated with other relevant risk factors (hypertension, age, 
diabetes, heart failure), jointly increasing the risk for mortality. In patients with 
diabetes mellitus renal impairment is seen more frequently and we can show in our 
study that renal impairment is an independent risk factor for long-term mortality. 
Consequently, we propose that even slightly impaired creatinine found at index stroke 
should be followed more closely to avoid worsening of renal function. It has even 
been proposed that renal impairment should be included in cerebrovascular risk 
scores (134), but  which level of impairment is discussed. 
Hyperlipidemia is a well defined and modifiable risk factor for ischemic stroke (229) 
and treatment with statins is recommended. However, several studies in vitro (230, 
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231) and in patients report a beneficial role of hyperlipidemia through mechanisms of 
neuroprotection (232-234) leading to a less severe neurological deficit and a 
decreased mortality. Furthermore, naturally low cholesterol levels - not as a 
consequence of statin use – are associated with increased short-term mortality (235, 
236). Following these observations it is considered that it is a statin effect and not the 
low colesterol itself predicting a better outcome (237).  At the time of inclusion in our 
study, statins were not routinely prescribed to stroke patients with low cholesterol 
values, and thus a confounding effect cannot be totally excluded.  
Hyperhomocysteinemia is in some studies suggested to be a risk factor for stroke 
(238, 239), but the latest AHA-guidelines do not recommend routine screening (128). 
Metabolic vitamin B12-deficiency is common among elderly (239). However, there 
seems to be increasing evidence that treatment with folic acid and vitamin B12 
(which is the treatment for hyperhomocysteinemia) reduces the risk for stroke (240-
242). Yet, some studies fail to confirm a possible beneficial effect of homocysteine 
lowering vitamin B-complex therapy on cardiovascular outcome, including stroke 
(195, 243).   
Anemia at the time of stroke worsens outcome and increases mortality (141). 
Reduced levels of blood hemoglobin are hypothesized to impair oxygen delivery to 
the brain and hinder neurological improvement and repair mechanisms during and 
after a stroke (139). We can confirm these findings in our study and advocate that 
even low-grade anemia should be followed up in stroke patients.  
 
5.2.3 Strengths and limitations 
The included patient cohort is representative for stroke patients in Norway, but it is 
not an epidemiological cohort study. The prospective patient inclusion, the long 
observational period, the large number of included patients, the strength of the 
statistical model and the control group with stroke free, sex and geographically 
matched control persons strengthens the validity of the results. However, the lack of 
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medical data in the control group and missing follow-up investigations are limiting 
the results. Additionally, some variables for the risk factors analyses were not 
available retrospectively and therefore some patients had to be excluded from these 
analyses. 
 
5.3 Paper III 
 
5.3.1 Nursing home placement  
Permanent institutionalization after stroke is related to the presence of hemiplegia 
(244) especially if it occurs in addition to functional and cognitive impairment, which 
are the strongest predictors of NH admission in general. A functional dependency in 3 
or more ADL areas is associated with higher odds for NHP (245). In our material, 
10.6% of the stroke patients were directly admitted to permanent NH, and 88.7% 
could be discharged to their homes either directly (44.7%) or after temporary 
rehabilitation (44.0%). These numbers are somewhat lower than those in other reports 
(181, 185), yet institutionalization rates vary widely due to geographical and 
socioeconomic factors, family prepositions, access to further rehabilitation as well as 
distribution of health insurances. The intensity of rehabilitation is also known to 
influence necessity of ensuing NHP. Early supported discharge (ESD) increases 
chances that stroke patients can live at home after the initial stay on the stroke 
ward(246). As we do not have information about the intensity of rehabilitation that 
was performed we weren’t able to make according correlations. 
The stroke patients initially discharged home stayed at an increased risk for 
permanent NHP compared to the age- and sex matched stroke free controls (37.2% 
versus 19.9%).  They were also admitted to NH earlier than their controls, and they 
died earlier confirming that a stroke is a major risk factor for death. 
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The different stroke types in this study were not associated with increased risk for 
NHP, but in general it is assumed that hemorrhagic strokes and ischemic strokes 
caused by atrial fibrillation are associated with bad outcome (247, 248).  
In all patient groups in this study, the length of the stay in NH was equal and in 
general quite short: only 1.6 years (SD 1.9) until death (or study end) for all patients 
and 1.5 years for the stroke-free controls. This might be caused by the similarity of 
the overall criteria for NHP for all types of patients in the Norwegian Health Care 
system, based on an individual assessment of the combination of cognitive and 
functional impairment accompanied by lack of support and assistance in daily living. 
The age at NHP for all stroke patients was equal, 81 years for the patients directly 
admitted after their stroke and 82.2 years for the patients primarily dismissed home, 
while stroke-free controls were admitted first at higher age (85.5 years). The interplay 
of stroke-related disability and age seems to be the most plausible explanation for this 
age difference.  
 
5.3.2 Risk factors 
Most studies describe NHP only as a discharge destination and the final length of the 
placement is not known. We show here that the length of NHP did not differ between 
the stroke patients and the stroke free controls, indicating that incurring costs for 
NHP for each individual may not differ significantly. However, as significantly more 
stroke patients are admitted to nursing home there is no doubt that the economic 
burden is relevant for society. Identifying risk factors for NHP is important to reduce 
this burden by aiming to prolong the time staying at home for each patient.  
In this study only the patients` first stroke was considered and cognitive assessment 
was not registered. Several studies affirm that recurrent strokes, cognitive deficits, 
depression and low physical activity level prior to stroke are risk factors linked to 
NHP after stroke (178). Health insurance status is an issue in some countries (185), 
providing unequal possibilities for rehabilitation and care but is not an issue in 
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Norway where all inhabitants have the same rights through the Norwegian Health 
Care system. 
Patients that could be discharged home were not surprisingly younger, they cohabited 
more often and their functional status before the stroke was better. Their strokes were 
less severe, and they suffered less atrial fibrillation and cardiovascular comorbidity. 
But they smoked more. Smoking is negatively associated with direct NHP or NHP at 
a later time point. This tobacco paradox is found as well in patients with acute 
coronary syndrome (249) and inconsistently found in earlier studies, most probably 
explained by residual confounding.  
However, regression analyses showed that only age (p<0.001) and severity of the 
stroke (p=0.014) were significant predictors for NHP when all risk factors were 
included. For the patients initially discharged to their homes only age was a factor 
influencing NHP (OR 1.053-1.125, p<0.001). 
 
5.3.3 Strengths and limitations 
The long observational period, the prospective patient inclusion, the stroke free, age- 
and sex matched control group and the complete nursing home registry in our 
community strengthen the results. Significant advances have been made over the last 
decades in terms of treatment protocols and secondary prevention changing the 
prospects of disability and mortality and this must be considered. The lack of follow-
up investigations and medical data of the control group are clear limitations of the 
study. In addition, the health care systems policy for care of the elderly with 
impairments has changed over the study period.  
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6. General conclusions 
Paper I: We have followed long-term mortality in patients with carotid stenosis, 
comparing patients on statin treatment with statin-naïve patients. Statin treatment was 
associated with markedly increased long-term survival. This effect was long-lasting 
and with a persistent increase over time and may be caused by a more general statin 
effect. 
Paper II: We analyzed the long-term survival in stroke survivors and compared it to 
sex- and age matched, stroke free controls from the same geographical area. Stroke 
patients had a significantly increased mortality. The mortality risk stayed continually 
increased for at least 10 years. Beside of the known risk factors age, diabetes, and 
stroke severity also low cholesterol and hemoglobin as well as elevated creatinine and 
homocysteine at index stroke were risk factors for mortality. 
Paper III: We analyzed the proportion of stroke survivors needing permanent NHP 
as compared to stroke-free matched controls. Almost 90% of the stroke patients could 
be dismissed home after their stroke. Stroke patients initially discharged home were 
admitted to a nursing home significantly more often and earlier than their controls – 
but only age was a risk factor for NHP. The stroke patients did not stay longer than 
other patients in the nursing homes, which is in accordance with the health care 
systems general policy that the total situation with general functional and cognitive 
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Statin therapy has an established role in the treatment of arterio-
sclerotic disease and in secondary stroke prevention. Up to 20% of
relative risk reduction in major vascular events per 1 mmol/L decrease
in LDL cholesterol is reported [1]. Atherosclerotic carotid stenosis is an
important risk factor for stroke and the inflammatory process of
arteriosclerosis is shown to be most pronounced in the early stages. We
have earlier shown that statin treatment may prevent and even reverse
the progression of stenosis in the internal carotid artery (ICA) over time
[2,3]. We have now 10 years later investigated survival and causes of
death during the long-term follow-up of the same patients with and
without statin treatment.
From August 1st 1994 until December 31st 1997 all outpatients
referred consecutively to the cerebrovascular ultrasound laboratory of
the Stavanger University Hospital were evaluated for study participation
andwere included independently of the reason for admission. Inclusion
criteria are described in detail previously (2). All included patients
(n=291) had a stenosis≥40% in one or both ICA as determined with
ultrasound examinations. Patients with endarterectomy of the stenosis
(n=32) or occlusion of the carotid artery (n=20) were excluded from
the study, as were the 9 patients where the collected data were
considered not reliable. 230 patients were included in this study,
informed consent given at first examination. The use of statins was at
this time not established as mandatory in patients with atherosclerotic
disease, and the decision to start with statin therapy was at the
discretion of their general practitioner and not influenced by the study
team before baseline examination and during follow-up. The study
patients were followed until death or to the end of the observation
period on May 1st, 2011. During this period information on statin
treatmentwas collected through the hospital files and information from
the patients' general practitioner. Information on date and cause of
death as the primary outcome variable in this study was obtained as
ICD-10 classification codes from the Norwegian Cause of Death Registry.
The study was conducted in accordance with the Declaration of
Helsinki; the protocol was approved by the Ethics committee of the
University of Bergen. The authors of this manuscript have certified that
they complywith the Principles of Ethical Publishing in the International
Journal of Cardiology.
Based on the collected information on statin use, the 230 patients
were categorized into three groups: 1. Never used statins, 2. Statin
treatment, and 3. Part time statin treatment. Patients in the first group,
Never used statins (n=60) had not been treated with a lipid lowering
drug during the study period. Patients, who were classified as on Statin
treatment (n=111), were already on statin treatment at baseline and
stayed on statin therapy throughout the study period. Patients classified
as Part time statin treatment (n=59) were on statin therapy for a
shorter or longer time period but not the whole study period. Of these
59 patients 54 (91.5%) started after baseline while 5 patients were on
the drug at baseline and stopped treatment with statins later on.
Baseline characteristics and causes of death were examined
using one-way analysis of variance (ANOVA) and chi-squared test
as appropriate. We used Cox proportional hazards models to
elaborate associations with mortality. In all Cox models, patients
were followed from baseline to death, or to May 1st 2011, for those
still alive. Age at baseline and sex were entered as covariates. In
order to strictly exclude an age effect on mortality we additionally
age-matched patients on statin therapy with patients never on
such therapy individually and repeated the Cox hazard models.
This procedure yields equal group distributions regarding age.
Statistical analyses were performed using the statistical software
SPSS 18.02. p-Values less than 0.05 were considered statistically
significant.
Of the 230 patients included at baseline, 125 (54.3%) had died at the
end of the study period. The mean time from study inclusion to death
was 12.8 years (range 1.5–16.8). Demographic and clinical variables at
baseline are given in Table 1. There were no significant differences in
gender, smoking habits, history of cardiovascular events, prevalence of
diabetes or hypertension, or the degree of ICA stenosis. Patients on statin
treatment were younger (67 years (SD 8.2) vs. 69.4 years (SD 7.7) in the
Part time statin treatment group and 74.4 years (SD 8) in Never used
statins group (pb0.001)), andhad lower cholesterol levels at study start.
As age at baseline was substantially different between the groups, a
secondary analysis of individually matched persons from the groups
Never used statins and Statin treatment was done. These two groups
(n=46) were matched individually according to age at baseline (mean
age 72.3 years (SD 7.9)). In these matched cohorts patients not using
statins were more likely to smoke (45% vs. 19.5%, p=0.004) and had
significantly higher cholesterol levels at baseline (6.23 vs. 4.99,
pb0.001) (Table 2). Mortality rates differed markedly between patients
on statin treatment and patientswithout statin treatment: In the patient
group Never used statins 53 patients (88.3%) had died, while 44 patients
(39.6%) in Statin treatment group and 28 patients (47.4%) in the Part
time statin treatment group had died. The difference stayed highly
significant after adjustment for age and cholesterol levels (Fig. 1). The
Cox-regression showed that statin treatment was a significant predictor
for lower mortality, with a hazard ratio (HR) of 0.27 (Cl 0.16–0.44,
pb0.001) for the Part time treatment group and a HR of 0.311 (Cl 0.19–
0.5, pb0.001) for the Statin treatment group. The difference inmortality
between the two age-matched groups remained highly significant in
this analysis after adjusting for age and current smoking (Fig. 2). Statin
treatment was associated with a significant lower HR of mortality,
HR=0.344 (Cl 0.19–0.61, pb0.001). There were no significant differ-
ences in the causes of death in the different patient groups (Table 3).
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In this study treatment with statins seems to markedly increase
long-term survival in individualswithmoderate to severe stenosis of the
ICA but not due to a relative reduction in vascular causes of death. The
Asymptomatic Carotid Artery Progression Study trial statins appeared to
reduce the risk of mortality after 3 years of follow-up [4]. Subsequent
studies confirm longer survival in patients on statin treatment [5–7] and
in the large Heart Protection Study (HPS) a 14% proportional reduction
in mortality among statin users was found [8]. The recent follow-up
study with a secondary open study phase had a total mean observation
time of 11.0 years [9] and the superior survival among the statin users in
the blinded first study period was preserved but did not increase during
the extended follow-up. Decreased mortality was caused by a reduction
in vascular related causes of death, while non-vascular causes were only
mildly reduced.
In the current study we have followed the patients for a mean of
12.8 years, and we found a markedly increased calculated survival
among individuals taking statins during this long follow-up time when
controlling for age and baseline cholesterol levels. In addition, as age is
the most important predictor for death, the second analysis where
patients with and without statins were matched individually for age
confirmed the results and showed a marked favorable long-term
survival in those using statins. The results from our study further
strengthen the suggested reduced mortality by using statins and also
show that the positive effect is not only long-lasting but also has a
persistent increase in effect over time.
In our study the causes of death were nearly identical in both the
treated and non-treated patient groups. The fact that there did not seem
to be a selectively reduced mortality due to vascular causes, may
indicate that the improved survival related to the use of statins could be
caused by decreased mortality also from the other causes of death. Thus
the extended survival in patients on statin medication must be
explained by other, more general effects of statins [10,11].
Current treatment guidelines emphasize the indication for statins in
patients with high cholesterol levels and in patients with cardiovascular
risk factors. Yet, the rather remarkable effects observed in the current
study may indicate that a wider patient group could benefit from statin
treatment. This probability could be examined in randomized controlled
studies with elderly individuals that do not fulfill established criteria for
treatment with statins.
The presented study has several limitations: Treatment stratification
was not performed at random and confounding by indication cannot be
excluded. Compliance is not measured and cholesterol levels during
follow-up are missing.
In conclusion, we show a rather marked longer survival in patients
with moderate to severe carotid stenosis being on statin medication as
compared to patients not taking statins. It seems that a more general
effect or maybe interplay of several additive beneficial effects of statins
is causing the prolonged survival. These effects could potentially also be
relevant in the general population with important consequences for
health and survival.
Table 1
Demographic and clinical variables of the patient groups at baseline according to treatment with statins.
All patients Statin treatment Part time treatment Never used statins p-Value
n=230 n=111 n=59 n=60
Mean age, years (SD) 69.5 (8.5) 67 (8.2) 69.4 (7.7) 74.4 (8) b0.001
% females 53.5 57.7 49.2 50 0.46
% ever smoked 64.2 65.7 63.2 62 0.89
% current smoking 27.8 21.9 29.8 38 0.1
% hypertension 55.2 58.6 54.2 50 0.55
% diabetes mellitus 12.6 11.7 11.9 15 0.81
Mean total cholesterol mmol/l, baseline (SD) 5.57 (1.28) 4.9 (0.9) 6.3 (1.4) 6.3 (1.1) b0.001
Mean degree carotid stenosis % (SD) 59.8 (12.3) 60.6 (14.2) 55.6 (11.6) 62.5 (15.6) 0.097
Previous cardiovascular event % 44.3 45.0 35.6 51.7 0.21
Statistical analysis: One way analysis of variance (ANOVA) and chi-squared test as appropriate.
Table 2
Age matched patient groups: Demographic and clinical variables at baseline according









Mean age, years (SD) 72.3 (7.7) 72.3 (7.9) 72.3 (7.9) 0.98
% females 54.3 56.5 52.2 0.68
% ever smoked 57.1 52.3 62.5 0.34
% current smoking 29.8 15.9 45 0.004
% hypertension 53.3 63 43.5 0.06
% diabetes mellitus 17.4 17.4 17.4 1
Mean total cholesterol
mmol/l (SD)
5.5 (1.07) 5.0 (0.8) 6.2 (1) b0.001
Mean degree carotid
stenosis % (SD)
62.8 (14.6) 62.7 (13.6) 62.8 (15.6) 0.67
Previous cardiovascular event % 47.8 47.8 47.8 1
Statistical analysis: One way analysis of variance (ANOVA) and chi-squared test as
appropriate.
Fig. 1. Survival curves of the patient groups according to treatment with statins. The
curves are adjusted for age and cholesterol levels.
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Fig. 2. Survival curves of the individually age-matched patient groups according to
treatmentwith statins. The curves are adjusted for cholesterol levels and current smoking.
Table 3
Cause of death among all deceased patients according to treatment with statins or not.
Statin treatment Never used statins p-Value
n=170, 72 deceased n=60, 53 deceased
Cerebrovascular 9 (13%) 7 (13%) 0.56
Cardiovascular 30 (42%) 18 (34%) 0.38
Pulmonary related 7 (10%) 5 (9%) 0.96
Cancer related 17 (24%) 10 (19%) 0.53
Other 9 (13%) 13 (25%) 0.08
Statistical analysis: One way analysis of variance (ANOVA) and chi-squared test as
appropriate.




Long-TermMortality and Its Risk Factors in Stroke Survivors
Sara Maria Mathisen, MD,*†‡ Ingvild Dalen, PhD,† Jan Petter Larsen, MD, PhD,†
and Martin Kurz, MD, PhD*‡
Background: Stroke is one of the leading causes of mortality worldwide. Under-
standing the risk factors associated with stroke mortality is important to improve
patient management. Few studies have examined long-term mortality and its as-
sociated predictive risk factors. Methods: We examined long-term mortality in 1137
patients with acute stroke and compared it to a geographically age- and sex-
matched, stroke-free control group. We followed the stroke patients for as long
as 16.4 years. In 1018 of these patients we assessed the effect of demographic,
clinical, and hematological factors on mortality. Results: At the end of the study
period, 51.7% of the patients and 32.7% of the stroke-free control individuals had
died (hazard ratio 2.2, confidence interval 1.9-2.5, P < .001). A total of 72.5% of
the patients and 53% of the controls with 12 years’ follow-up (n = 570) had died
(P < .001). Regression analyses indicate that, in addition to known risk factors such
as age, diabetes, and stroke severity, both low cholesterol (P < .001) and hemo-
globin (P < .002), hyperhomocysteinemia (P = .005), and elevated serum creatinine
(P < .001) at index stroke are associated with increased long-term mortality. Conclusions:
Stroke patients surviving the first year after stroke have a markedly increased
mortality rate as seen in long-term follow-up. Furthermore, the results from this
study indicate that changes in creatinine, homocysteine, and hemoglobin should
be followed more carefully as standard practice after acute stroke. Key Words:
Stroke—long-term—mortality—risk factors—homocysteine—creatinine.
© 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Introduction
Stroke is one of the leading causes of mortality world-
wide with about 6 million people dying annually.1 The
risk of death from stroke is greatest in the first few weeks
after the stroke. The resulting brain injury and secondary
complications, due in part to immobilization,2-5 are the
main causes for this short-term mortality.
The risk factors for long-term mortality after stroke are
less investigated,6,7 but existing evidence suggests that they
differ in part from the short-term risk factors. Stroke se-
verity, age, and cardiovascular risk factors2,4,7-9 are prominent
predictors for mortality within the first year after stroke,
whereas age, male gender, smoking, and diabetes are pre-
dictors for long-term mortality.10-12 Few studies6,7 have
investigated long-term mortality and compared the mor-
tality rates of stroke patients with a stroke-free, age- and
sex-matched control group from the general population
living in the same geographical area. In young stroke sur-
vivors (18-50 years), the cumulative 20-year mortality
compared to the general population exceeded expected
mortality for decades after the initial stroke.13 Aware-
ness of long-term mortality and its clinical predictors offers
the opportunity to better regulate these risk factors in
poststroke follow-up.
In the present study, we analyzed the long-term mor-
tality rates in 1137 stroke patients hospitalized for stroke
in the county of Rogaland, Norway, from 1996 to 2004.
The patients were followed up for up to 16.4 years and
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the mortality rates were compared to a stroke-free, age-
and sex-matched group from the general population derived
from the same geographical area. The risk factors pre-
dicting mortality were identified in the stroke patient group.
Materials and Method
Patients and Controls
All patients admitted to the stroke unit at Stavanger
University Hospital between January 1, 1996, and March
31, 2004, were included in the study (n = 1472). At this
time, the stroke unit was composed of 6 acute stroke beds
that were continuously occupied by consecutive pa-
tients. If there was no capacity for new patients at the
stroke unit, these patients were admitted to a general
medical ward, but due to a lack of structured follow-
up, these patients were not included in the study.
Demographic variables, medical history, and results of
the radiological, laboratory, and clinical investigations were
recorded on study inclusion (baseline) (Table 1). Neuro-
logical deficit was assessed clinically using the Scandinavian
Stroke Scale (SSS).14
Information on death was collected through linkage to
the National Population Register of Statistics (Statistics
Norway) and the National Registry of Death, Norway,
until May 31, 2012.
The control group was obtained from the National Pop-
ulation Register of Statistics. Reference individuals were
acquired arbitrarily from the general population but were
individually matched 1:1 according to sex, age (born on
the same year as the index patient), and residency on
the same year the patient was hospitalized for stroke.
Initially, 1472 acute stroke admissions were recorded.
In case of repeated admissions during the study period,
only the index stroke was taken into account. Thus, 82
multiple registrations were removed. Thirteen patients of
foreign nationality were excluded as they were not reg-
istered in the National Population Register of Statistics.
Furthermore, we excluded the patients who died within
the first year of the stroke (n = 72) and their matched
control persons as we aimed to assess long-term
mortality (Fig 1).
To have a stroke-free control group for the mortality
analysis, we examined the hospital files of the control
Table 1. Demographic and clinical variables at baseline according to analysis
Variables Factors
Mortality analysis Missing Risk factor analysis Missing
n = 1137 n n = 1018 n
All patients Mean age at inclusion (years) 66.8 (SD 14.3) 0 67.6 (SD 14.4) 0
Dead at study end (%) 51.7 0 50.6 0
Male (%) 54.6 0 54.1 0
SSS score at admission (mean) 46.3 (SD 13.8) 409 46.0 (SD 14) 154
SSS score at discharge (mean) 50.4 (SD 11.8) 424 50.2 (SD 12) 215
Cerebrovascular subtype Infarct (%) 73.5 0 73.2 0
Hemorrhage (%) 10.7 0 10.7 0
TIA (%) 15.8 0 16.1 0
Risk factors Previous cardiovascular event (%) 40.8 0 44.1 0
Cardiovascular heredity (%) 18.3 245 18.4 7
Hypercholesterolemia (%) 27.8 0 27.0 0
Diabetes (%) 12.3 0 10.4 0
Hypertension (%) 51.8 0 50.3 0
Smoking (current or previous) (%) 39.8 47 41.2 47
Atrial fibrillation (%) 9.3 238 10.9 140
Carotid stenosis (%) 24.6 9 27.2 8
Hyperhomocysteinemia (%) 22.0 239 23.5 1
Mean values (SD) Cholesterol value (mmol/L) 5.5 (1.2) 247 5.5 (1.2) 12
HDL cholesterol (mmol/L) 1.3 (.4) 282 1.3 (.4) 51
Triglyceride value (mmol/L) 1.4 (.7) 259 1.4 (.7) 25
Creatinine value (μmol/L) 86.9 (25) 239 87.2 (25) 1
CRP at admission (mg/L) 16.3 (26) 238 16.7 (29) 0
Glucose value (mmol/L) 5.9 (1.5) 288 5.9 (1.5) 24
Cobalamine value (pmol/L) 328 (219) 371 330 (223) 154
Homocysteine value (μmol/L) 13.6 (8) 400 13.9 (9.1) 183
Hemoglobine value (g/dL) 13.9 (1.5) 240 13.9 (1.5) 2
Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; SSS, Scandinavian Stroke Scale; TIA, transient ischemic attack;
SD, standard deviation.
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group for stroke diagnoses. Individuals with a stroke or
a transient ischemic attack (TIA) diagnosis (431, 434, 435
in the International Classification of Diseases [ICD]-8 and
ICD-9, I61 and I63 with subclasses in ICD-10) (n = 168)
were excluded from the control group along with their
corresponding index patient for the mortality analysis.
In the control group, no clinical data were available at
baseline or during follow-up; thus, the analysis of long-
term mortality was performed in 1137 patients and in
an equal number of reference individuals (Fig 1).
The risk factor analyses were performed in 1018 stroke
patients; 287 patients were excluded due to missing
relevant data (Fig 1).
Clinical and Demographic Variables at Baseline
Data for age, gender, occupation, marital status, and
residency at the time of stroke were complied. Pre-
existing cardiovascular disease, hypertension, smoking,
diabetes, heredity for cardiovascular disease, presence of
carotid artery stenosis measured by ultrasound,15 stroke
severity (SSS), electrocardiogram findings, and blood pres-
sure on admission were also noted. In addition blood levels
of hemoglobin, cholesterol, triglycerides, high-density li-
poprotein cholesterol, homocysteine (Hcy), creatinine,
C-reactive protein, glucose, and HbA1c were recorded on
admission. The index stroke type was further classified
into cerebral infarction, intracerebral hemorrhage, or TIA.
Statistics
The basic statistical analyses were performed in IBM
SPSS version 22 (IBM Corp., Armonk, NY, USA). A Kaplan–
Meier plot illustrates the observed survival in patients
and their matched controls. Chi-squared tests were used
to compare the survivor fraction between both groups
at different time points. A shared frailty model was fitted
in R (R Core Team, Vienna, Austria) (package survival,
function coxph for Cox regression) to compare overall
mortality between the stroke patients and their matched
controls. The analysis of risk factors for death among stroke
survivors was also performed using coxph. The risk factors
considered are listed in Table 1. All continuous vari-
ables were standardized before the analysis, and covariates
contributing little to the fit of the model were removed
from the model. The effects of predictors with evident
nonlinear effects were modeled by multivariable frac-
tional polynomials using the package mfp. The proportional
hazards assumption was tested by examination of
Schoenfeld residuals by function cox.zph. Models were
compared by likelihood ratio tests. All excluded vari-
ables were reintroduced into the final model to check for
confounding effects. The predictive ability of the final
model was estimated by Harrell’s concordance/C-
index, using the function validate in the rms package,
with B = 150 bootstrap samples. For all analyses, we con-
sidered a P value less than .05 to be significant.
Ethics
The study was approved by the Regional Ethics Com-
mittee for Medical Research Ethics, University of Bergen.
The authors have no disclosures.
Results
A total of 1137 patients were included in the mortal-
ity analysis and 1018 patients in the risk factor analysis.
The demographic and clinical variables of the patients
with acute stroke included in the different analyses are
shown in Table 1. There were no statistically significant
differences between the baseline data of the patient groups
included in the analyses.
Mortality Analysis
Table 1 presents the characteristics of the 1137 pa-
tients included in the mortality analysis. The mean age
at stroke was 66.8 years. Among the patients, 73.5% had





Multiple admissions n = 82
Mortality data not 
available n= 13
Reference patient suffered a 
stroke n = 168
Lack of baseline data n = 287
Mortality data analysis
(Comparison with reference 
population)
Risk factor analysis
Died during first year n= 72
1305Figure 1. Flowchart explaining patient selec-
tion and study design.
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rhage, and 15.8% of the patients were diagnosed with a
TIA. A total of 51.8% of the patients had hypertension,
12.3% diabetes, and 9.3% atrial fibrillation.
Among the stroke patients, 51.7% had died at the end
of the study period, as compared to 32.7% of the con-
trols (risk ratio [RR] = 1.58, 95% confidence interval [CI]
1.43-1.75, P < .001). The mortality rate for stroke pa-
tients compared to the controls was 2-fold higher (hazard
ratio 2.2, CI 1.9-2.5) and stayed continuously elevated
during the study period (Fig 2). Not all patients had an
equal follow-up time due to different years of inclusion
and varying times of death: 26.7% (n = 303) had died after
5 years as compared to 16.8% (n = 191) of the controls
(P < .001); after 10 years of follow-up, the respective per-
centages of deaths were 57.3% (n = 526) and 37.4% (n = 316,
P < .001), and after 12 years 72.5% (n = 570) and 53%
(n = 355, P < .001).
Risk Factor Analysis
Table 1 shows the demographic and clinical data at the
time of stroke including mean age at stroke (67.6 years),
gender (54.1% male), and stroke type. At the end of the
study, 50.6% of the stroke patients had died. Of all the
variables recorded and included in the analysis, seven
were significantly associated with death among stroke pa-
tients over time. As expected, age (P < .001), stroke severity
(low SSS score) (P < .001), and diabetes (P = .004) were
risk factors for mortality after stroke. The analyses also
showed that hyperhomocysteinemia (P = .005), lower he-
moglobin values (P = .002), elevated creatinine (P < .001),
and hypocholesterolemia (P < .001) (Table 2) were risk
factors associated with increased mortality over time. The
impact of the risk factors stayed unchanged during the
observational period.
Discussion
In the present study, we followed stroke patients sur-
viving the first year after acute stroke and compared the
mortality risk with a stroke-free control group for up to
16.4 years. At the end of the study period, 51.7% of the
Figure 2. Kaplan–Meier curve illustrating sur-
vival for the stroke patients (green line) versus
the stroke-free controls (blue line). (Color version
of figure is available online.)
Table 2. Factors associated with death among stroke patients
surviving their first year
Variable HR (95% CI) P
Age 2.16 (1.9-2.4) <.001
Cholesterol .84 (.8-.9) <.001
Creatinine 1.35 (1.1-1.6) <.001
Hemoglobin* 1.04* (1.0-1.1) .002
Diabetes 1.51 (1.1-2.0) .004
Homocysteine 1.37 (1.1-1.7) .005
SSS score 40-49 1.46 (1.1-1.9) .003
SSS score 20-39 1.55 (1.2-2.0) .001
SSS score 0-19 2.20 (1.6-3.1) <.001
Abbreviations: CI, confidence interval; HR, hazard ratio; SSS,
Scandinavian Stroke Scale.
Risk factors associated with increased mortality (HR) during long-
term follow-up among stroke patients surviving the first year after
stroke.
*Hemoglobin is transformed by 1/√; that is, a lower hemoglobin
level increases HR.
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patients and 32.7% of the stroke-free control individuals
had died (hazard ratio 2.2, CI 1.9-2.5, P < .001). Regres-
sion analyses indicate that, in addition to known risk factors
such as age, diabetes, and stroke severity, low choles-
terol, hemoglobin, and elevated levels of creatinine and
Hcy at index stroke were associated with increased long-
term mortality. The mortality risk stayed consistently
increased for at least 10 years.
Short-term mortality in stroke patients is intensively
studied and is at its highest during the first 30 days.16
Patients surviving the first year also have a higher
mortality risk than the general population, but few
studies have long-term follow-up information. In the
studies conducted, 12-year mortality rates vary from
15.7%17 in younger patients to as high as 86.5%18 in
older patients. In younger patients, it is shown that the
increased mortality rates continue across decades, im-
plying that the underlying (vascular) disease process
continues to elevate the risk for vascular disease through-
out their lives.13 In our patients, 51.7% had died at the
end of the study, but in the patients with a complete
12-year follow-up, 72.5% had died as compared to only
53% of the controls. Kaplan–Meier curves showed that
the mortality was persistently increased during the entire
study period.
The risk factor analysis confirmed that age, diabetes,
and stroke severity are risk factors for increased mortal-
ity in stroke patients. Long-term mortality was also
associated with elevated values of creatinine and Hcy as
well as low cholesterol and hemoglobin levels at the time
of the acute stroke. Ischemic heart disease, atrial fibril-
lation, hemorrhagic stroke, and previous stroke are suggested
to be significant predictors for long-term mortality,7 but
these were not found to be significant in our study.
Subtle renal impairment (high normal serum creati-
nine) is a marker of increased cerebrovascular disease risk19
and is associated with other relevant prognostic risk factors
(hypertension, age, diabetes, heart failure), leading to the
claim that renal impairment should be included in cere-
brovascular risk scores.20 This was supported by our data
showing that even slightly elevated creatinine levels predict
increased mortality over time.
Hyperhomocysteinemia is a known risk factor for
stroke,21 but its relevance is debated. Smaller studies have
shown that elevated Hcy promotes cerebral, arterial, and
venous thrombosis, and may predispose to premature ath-
erosclerosis, craniocervical arterial dissection,22 and increased
oxidative stress23 and can be assessed with long-term
mortality.24 Even though hyperhomocysteinemia is gen-
erally acknowledged as a treatable risk factor for
atherotrombotic diseases and stroke, the latest guide-
lines from the American Heart Association25 do not
recommend routine screening. Our data suggest that
hyperhomocysteinemia might be a risk factor for in-
creased long-term mortality in acute stroke patients and
we recommend further studies.
Hyperlipidemia is a well-defined and modifiable
risk factor for ischemic stroke,26 and the use of statins
has been thought to contribute to a decline in stroke
mortality.27 Surprisingly, several studies also report a ben-
eficial role of hyperlipidemia through mechanisms of
neuroprotection28,29 leading to a less severe neurological
deficit and thus a decreased mortality. However, low cho-
lesterol levels without use of statins are associated with
increased short-term mortality30,31; therefore, it is only cho-
lesterol reduction due to statin use that predicts a better
functional outcome.28,32 Our findings suggest a possible
negative association between hypercholesterolemia and
mortality. At the time of inclusion in the present study,
statins were not routinely prescribed to patients with low
cholesterol at the time of stroke, which may have con-
tributed to these results. Further trials are needed to assess
the impact of dyslipidemia treatment on stroke inci-
dence, outcomes, and mortality.
Diabetes is an established risk factor for stroke.
Compared to nondiabetic patients, diabetic patients
also have an increased risk of new vascular events
and death after stroke.33-35 Literature suggests that
hyperglycemia36-39 is a predictive factor for increased
stroke mortality. Several mechanisms are hypothesized,
including direct neurotoxicity and systemic consequences.40,41
Our results support that diabetes is a risk factor for
long-term mortality after stroke.
Anemia appears to have a significant effect on the func-
tional improvement and outcomes of ischemic stroke
patients, as it may increase the rate of complications and
decrease the efficacy of stroke rehabilitation.42,43 Reduced
blood hemoglobin levels may impair oxygen delivery to
the brain and hinder neurological improvement. A reduced
blood hemoglobin level is seen as a predictor of short-
and long-term mortality after stroke,44,45 in congruence
with our findings.
This study has several limitations. Although the in-
cluded patient cohort is representative of stroke patients
in Norway, the study is not an epidemiological cohort
study. Many advances have been made in terms of pre-
vention and mortality of stroke since we began our study.
Additionally, some variables for the risk factor analyses
were not available retrospectively, and therefore some pa-
tients had to be excluded from these analyses. Furthermore,
we lack medical data of the control group and follow-
up investigations.
The prospective patient inclusion, the long observa-
tional period, the large number of included patients, the
strength of the statistical model, and the control group
with stroke-free, gender, and geographically matched
control persons strengthen the validity of our results.
In conclusion, we have shown that stroke survivors after
the first year after acute stroke have a persistently and
nearly 2-fold increased risk of death during long-term
follow-up. Several of the risk factors associated with long-
term mortality can be modified. These factors, including
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creatinine, hemoglobin, and Hcy, should possibly be fol-
lowed up more intensely after patient discharge. We
therefore recommend further studies in independent patient
cohorts.
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Objectives: Stroke is one of the leading causes for nursing home placement (NHP). We 
havestudiedtheprognosisandriskfactorsregardingNHPforstrokepatientsinitially
discharged to their homes.
Materials and methods: AllstrokepatientsinthemunicipalityofStavanger,Norway,
between January 1, 1996, andMarch 31, 2004,were included and followed until
death or May 31, 2012. Time intervals for NHP and death were compared to an age- 
andsex-matched,stroke-freecontrolcohort.Logisticregressionanalysiswasusedto
assess risk factors for NHP.
Results: Atotalof452patientswere included.Atotalof48patients (10.6%)were
directlyplacedinanursinghome,while401patients(88.7%)weredischargedtotheir
homes;180patients(44.7%)directlyand221patients(55.3%)aftertemporaryreha-
bilitation.Of thepatientsdischargedto theirhomes,29.7%neededNHPata later
timepointascomparedto19.9%ofthecontrols(P<.001).Logisticregressionanalysis









K E Y W O R D S
dischargedestination,nursinghome,prognosis,stroke,strokesurvivor
1  | INTRODUCTION
Stroke is one of the leading causes of mortality and morbidity. 
Worldwide, about six million people are dying annually,1 and stroke 
isoneoftheleadingcausesfordisabilityandinstitutionalization.2 The 
prevalenceofstrokeisexpectedtoincreasesignificantlyintheyears
aheadasthepopulationabove65yearsincreases.3 In Norway, 15 000 
peoplesufferastrokeannuallyand55000Norwegianshavehadone
or more strokes.4 Two- thirds are consequently disabled,5 and stroke is 
conceived to be one of the main causes for disability and nursing home 
placement (NHP).
About half of the surviving stroke patients can be directly dis-
charged from hospital to their homes; the other half has a remain-
ingdisability requiringspecial servicesoreven institutionalizedcare
at some point.2,6-9Yet,reportedinstitutionalizationratesafterstroke
vary widely by population, setting, and duration of follow-up: 13-
45%ofstrokepatientsareinstitutionalizeddirectlyafterhospitaliza-
tion7,10,11and19-83%withinaperiodof5years.8,12-14Ageandinitial





stroke and live longer.19,20Notmuchisknownaboutthestrokepatients
initially discharged to their homes and if their prognosis regarding
mortalityandinstitutionalizationdiffercomparedtomatched,stroke-
free individuals. We have therefore examined the long- term need 
for institutionalizationof strokepatients initiallydischarged to their
homes.WehavefurtherelaboratedtheriskfactorsforNHP.Thetime
intervals between hospital discharge, NHP, and death were calculated, 
andtheproportionsandtimeperiodsbetweenNHPanddeathwere
compared.
2  | MATERIAL AND METHODS
2.1 | Patients and controls
All patients admitted to the stroke unit at Stavanger University




stroke unit, the patientswere admitted to a generalmedicalward,
and due to a lack of structured follow-up, these patientswere not
includedinthestudy.Alldatawerecollectedprospectivelybystroke
physicians and stroke nurses for internal quality assurance. Analyses 
forthecurrentstudywereperformedretrospectively. Inthecityof
Stavanger which is the largest municipality in the region with about 





ended at May 31, 2012.
The control group was obtained from the National Population
RegisterofStatistics (StatisticsNorway).Reference individualswere
acquired arbitrarily from the general population but individually
matched 1:1 according to sex, age (born the same year as the index 
patient),andresidency;thesameyearthepatientwashospitalizedfor
stroke. In the control group, no clinical data were available at baseline 





stroke, intracerebral hemorrhage, or transient ischemic attack (TIA)
(431,434,435inICD-8andICD-9,andI61andI63withsubclasses
in ICD- 10) were excluded along with their matched controls (n=22). In 
case of repeated admissions during the study period, only the index 
strokewastakenintoaccount,excluding31observations.
In order to have a stroke- free control group, we examined the hos-
pitalfilesof thecontrolgroupforstrokediagnoses. Individualswith
astrokeoraTIAdiagnosis (431,434,435 in ICD-8and ICD-9,and
I61 and I63 with subclasses in ICD- 10) were excluded along with their 
corresponding indexpatient (n=58,11.4%) leaving452patientsand
controls for analysis. Further, the patientswere divided into stroke
patients initially discharged to their homes (directlyor after tempo-
raryrehabilitation)(n=401)andpatientswhoweredirectlyandperma-
nentlyadmittedtoanursinghome(n=48).
2.2 | Clinical and demographic variables at baseline
Results of the radiological, laboratory, and clinical investigations
were recorded on study inclusion (baseline) (Table 1). Data for age, 




disease, hypertension, diabetes, smoking, heredity for cardiovascular 
disease,presenceofcarotidarterystenosismeasuredbyultrasound,
stroke severity (Scandinavian Stroke Scale22),ECGfindings,andblood
pressureonadmissionwerenoted.Inaddition,bloodlevelsofhemo-
globin, cholesterol, triglycerides, HDL cholesterol, homocysteine, cre-
atinine,CRP,glucose,andHbA1cwererecordedonadmission.The
indexstroketypewasclassifiedintocerebralinfarction,intracerebral
hemorrhage (ICH), or TIA.
2.3 | Statistics
ThestatisticalanalyseswereperformedinIBMSPSS22.0(SPSSInc,
Chicago, IL, USA). Chi- squared test was used for categorical variables 
andone-wayANOVAtocomparemeansforcontinuousvariables.For















admission and stroke subtypes are shown in Table 1.
In univariate analysis, the patients initially discharged to their
homeshadmoreoftenTIA (16.5%vs2.1%,P<.001), lessoften ICH
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(9.7%vs29.2%P<.001), less severe strokes (SSS 47 vs 29.2, P=.008),
andtheywereyounger(67.6vs80.8years,P<.001)thanthepatients
thatwere admitted directly to nursing homes.The patients initially
dischargedhomealsocohabitedmore(61.8%vs33.3%,P=.006), had 






stroke- free control group (n=401, P<.001).
Table2 shows that for the patients initially discharged to their
homes, age at stroke (76.4 vs 64.5 years, P<.001),femalegender(45%
malevs56%,P=.04),cohabitationstatus(48.3%vs31.7%livingalone,
P<.001), hypertension (65% vs 51.6%, P=.01), and functional level
(Barthel Index88.4vs94.4,P=.002) were associated with NHP at a 
latertimepoint.SmokingwasnegativelyassociatedwithNHP(32.1%
vs50.8%,P=.001)
At the end of the study, a total of 168 stroke patients (37.2%)
and 90 stroke-free controls (19.9%) had been permanently placed
in a nursing home (P<.001).Fifty-fourpercentofthestrokepatients
(n=244)and33.8%ofthecontrolindividuals(n=153)haddiedatstudy
end (P<.001).However,thesameproportionsofstrokepatientsand






inghome (81and82.2vs85.5years,P=.004) (Figure 1). The stroke 
patientswerealsosignificantlyyoungeratdeath(80.6vs83.9years,
respectively,P=.001).Therewasnodifference intimefromNHPto
death when comparing stroke patients initially discharged to their
homesandmatchedcontrols (1.7vs1.3years, respectively,P=.145) 
(Table 3).
Regression analyses showed that only age (P<.001) and severity 
of the stroke (P=.014)were significant predictors forNHPwhen all
factorswere included. For the patients initially discharged to their
homes,onlyagewasafactorinfluencingNHP(OR1.09,95%C.I.for
OR 1.053- 1.125, P<.001).




charged home divided into the patients that needed nursing home
(NH) later on and those who did not.
Kaplan- Meier curves describing age at nursing home admission for 
thepatientsadmitteddirectlyafterthestroke,thepatientsthatwere
discharged home but needed nursing home later and the stroke- free 
controls.
Time periods (years) from stroke to nursing home placement (NHP) 
andtodeathforthepatientgroupsasdescribedinTable1,aswellas
theunivariateanalysesbetweenthepatientgroupdischargedtotheir
homes and their matched controls.
4  | DISCUSSION
Inthisstudy,weshowthatthemajorityofourstrokepatients(88.7%)
were able to live at home either directly after their stroke or after
temporary rehabilitation. Yet, stroke patients discharged to their
homesneededNHPsignificantlymorefrequentlyandearlierthanthe
TABLE  2 Demographicdataatbaselineforthe401patientsthatweredischargedhomedividedintothepatientsthatneedednursinghome
(NH) later on and those who did not
Patients discharged home, 
later to NH (n=120) Missing
Patients not admitted  
to NH (n= 281) Missing P-value
Gendern(%male) 54 (45) 0 157 (55.9) 0 .04
Mean age in years at stroke (SD) 76.4(8.3) 0 64.5 (13.4) 0 <.001
Cohabitationstatus(livingalone)n(%) 57(48.3) 2 86(31.7) 10 <.001
Strokesubtype-Ischemicstroken(%) 92 (76.7) 0 204 (72.6) 0 .36
ICHn(%) 13(10.8) 0 26 (9.3) 0 .35
TIAn(%) 15 (12.5) 0 51(18.1) 0 .24
Hypertensionn(%) 78(65) 0 145 (51.6) 0 .01
Diabetesmellitusn(%) 16 (13.3) 0 31 (11) 0 .51
Smoking(current/previous)n(%) 36 (32.1) 8 131(50.8) 23 .001
Previouscardiovasculardiseasen(%) 44 (46.3) 25 89(35.3) 29 .06
Previousstroke/TIA/ICHn(%) 28(29.5) 0 48(19) 1 .1
Carotidstenosis>60%n(%) 33(28) 2 53(18.9) 1 .07
AtrialFibrillationn(%) 12 (13.3) 30 14 (6.3) 57 .06
Stroke severity by SSS mean (SD) 46.1 (10.7) 2 47.4(12.8) 7 .33
Barthelindexbeforestrokemean(SD) 88.4(22) 16 94.4(18) 39 .008
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stroke-free,age-andsex-matchedcontrolpopulationfromthesame
geographicalarea(29.9%vs18.5%).
In a recent study by Nguyen et al.,1678.2%ofacutestrokepatients
weredischargedtotheirhomesand21.8%placedinnursinghomes.
Internationally,institutionalizationratesvarybetween13%and45%
directly after hospitalization,10,11,16,23 and in our study, 10.6%were
admitteddirectlytoanursinghomeaftertreatmentforacutestroke.
Variations in NHP are due to geographical and socioeconomic fac-
tors, familyprepositions,access to further rehabilitation,andhealth
insurances.16,24-26 Further, age and stroke severity are well- known 




ESD (early supported discharge) increases the possibility for living at 
home,27butaswedonothavedetailed informationaboutthe level
of rehabilitation inourpatients,wehave thusnot includedsuchan
analysis in the current study.
OtherfactorsknowntobelinkedtoNHPafterstrokearecohab-
itation status, health insurance status, dysphagia, recurrent stroke,
intracerebralbleedings,cognitivedeficits,depression,and lowphys-




vascular comorbidity, were not living alone but they smoked more. The 
strokeswerelesssevereorTIAs,andthepreexistingfunctionalstatus
wasbetter.Atrialfibrillationisknowntobeamainreasonforsevere




these associations should be interpreted carefully. Yet future stud-
ies shouldprospectively followpatientsand include regularmedical
investigations.
Smoking was negatively associated with NHP both in patients
directlyadmittedtoanursinghomeorinpatientsplacedinanursing
homeata latertimepoint.Thistobaccoparadox isfoundaswell in
patientswithacutecoronarysyndrome29 and inconsistently found in 







All patients  
n=452
Patients discharged  







Deadatstudyend%(n) 54 (244) 97.9 (47) 48.1(193) 31.4 (126) <.001
Nursing Home Placement 
(NHP)%(n)
37.2(168) 100(48) 29.9 (120) 18.5(74) <.001
Mean age at NHP in years 
(SD)
81.8(8.2) 81(8.6) 82.2(8.1) 85.5(6.1) .004
Mean age at death in years 
(SD) 
80.6(10.2) 83.3(7.6)47 80(10.6)193 83.9(8.9) .001
Meantimefromstroketo
NHP in years (SD) n
4.2(3.6)168 0.2(0.3)48 5.8(3.1)119
Meantimefromstroketo
death in years (SD) n
5.0 (3.6) 244 2.3 (2.3) 47 5.7 (3.5) 153
MeantimefromNHPto
death in years (SD) n
1.6(1.9)148 2.1 (2.3) 47 1.3 (1.7) 101 1.7 (2.1) 62 .15
F IGURE  1 Kaplan- meier curves describing age at nursing home 
admission for the patients admitted directly after the stroke, the 
patients that were discharged home but needed nursing home later 
and the stroke- free controls
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wassimilar(81vs82.2years,respectively)whilestroke-freecontrols
wereadmittedsignificantlylatertonursinghomefacilities(85.5years)
(Figure 1). Interplay of stroke- related disability and age seems to be 
themostplausibleexplanationforthisagedifference.
Althoughstrokepatientsinourstudywereplacedmorefrequently
and significantlyearlier in anursinghome facility, the lengthof the




Health Care system, based on cognitive and/or functional impair-
ment accompanied by lack of support and assistance in daily living.18 
Especially,thefirstfactorsseemoftentobeexaggeratedbyastroke.31
Wehavepreviouslyshownthatstrokepatientsingeneralhavean













is relevant for society. In order to reduce this burden and in order to 
prolongthetimestayingathomeforeachpatient,it isimportantto
identifyriskfactorsforNHP.
The lack of follow-up investigation and the lack ofmedical data
ofthecontrolgrouparelimitationsofthisstudyaswellasthelackof
informationregardingdifferentlevelsofrehabilitation(especiallyESD).
Another limitation to consider is the significant advances that have
beenmadeovertime in termsof treatmentprotocolsandsecondary
prevention. Inaddition,thehealthcaresystem’spolicyforcareofthe
elderly with impairments has changed over the study period. Yet, the 
longobservationalperiod,theprospectivepatientinclusion,thestroke-
free, age- and sex- matched control group, and the complete nursing 
home registry in our community strengthen the results from this study.
In conclusion, we have shown here that the majority of stroke 
survivorsareabletobedischargedtotheirhomes,buttheyarestill
in need of earlier and more frequent NHP during follow- up than an 
age-andsex-matched,stroke-freecontrolgroup.Afterinitialhospital
discharge, only age is found to be a risk factor for NHP. Length of NHP 
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